Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Conditions: Venous Thromboembolism
Sponsor: Brigham and Women's Hospital

Replication of the AMPLIFY Anticoagulant Trial in Healthcare 
Claims Data 
NCT 00643201 
May 25, 2021 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
1. RCT Details 
This section provides a high-level overview of a published RCT that the described real-world evidence study is trying to replicate 
as closely as possible given the remaining limitations inherent in the healthcare databases. 
 
1.1 Title 
Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY) 
 
1.2 Intended aim(s) 
To compare the risk of symptomatic, recurrent venous thromboembolism (VTE) in patients with symptomatic deep vein 
thrombosis (DVT), pulmonary embolism (PE), or both for apixaban versus standard therapy of warfarin. 
 
1.3 Primary endpoint for replication  
The primary outcome of the study was symptomatic, recurrent VTE or death related to VTE 
 
1.4 Required power for primary endpoint and noninferiority margin (if applicable) 
Assuming a non-inferiority margin of 1.80, it was determined that 4,094 patients would be needed to achieve 90% power to 
conclude noninferiority of apixaban over standard therapy at one-sided alpha level of 0.025.  
 
1.5 Secondary endpoint for replication (assay sensitivity) and RCT finding 
Major bleeding; RR= 0.31 (95% CI 0.17–0.55) 
 
1.6 Trial estimate 
 
RR = 0.84 (95% CI 0.60-1.18) comparing apixaban vs standard therapy (Agnelli et al., 2013) 
 
2. Person responsible for implementation of replication in Aetion 
Dureshahwar Jawaid, MPH implemented the study design in the Aetion Evidence Platform. She is not responsible for the validity of 
the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform. 
 
3. Data Source(s) 
Optum, MarketScan, Medicare  
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
4. Study Design Diagram 
The study design diagram visualizes key aspects of the longitudinal study design for expedited review.  
 
Figure 1.  
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
5. Cohort Identification  
 
5.1 Cohort Summary 
This study will involve a new user, parallel group, propensity score-matched, retrospective cohort study design comparing 
apixaban to warfarin users. The patients will be required to have continuous enrollment during a baseline period of 180 days 
before initiation of apixaban or warfarin (index date). We will restrict the analyses to patients with a diagnosis of proximal DVT, 
PE, or both. 
 
5.2 Important steps for cohort formation 
 New use of apixaban, exposure, and warfarin, comparator, is defined as no use of either therapy in the 180 days prior to index 
date. 
 
5.2.1 Eligible cohort entry dates 
Market availability of apixaban in the U.S. for treatment of deep vein thrombosis and pulmonary embolism started on 
August 21, 2014 
• For Medicare: August 21, 2014 – December 31, 2017 (end of available data)  
• For Marketscan: August 21, 2014 – December 31, 2018 (end of available data)  
• For Optum: August 21, 2014 – March 31, 2020 (end of available data)  
 
5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date. 
Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion 
are provided in Appendix A and are summarized in the flowcharts below. 
 
5.3 Flowchart of the study cohort assembly 
 
Optum 
Marketscan 
Medicare 
 
Less 
Excluded 
Patients 
Remaining 
Patients 
Less 
Excluded 
Patients 
Remaining 
Patients 
Less 
Excluded 
Patients 
Remaining 
Patients 
All patients 
 
77,673,639 
 
200,203,908 
 
6,886,908 
Did not meet cohort entry criteria 
-76,868,532 
805,107 
-
199,645,422 
558,486 
-4,150,733 
2,736,175 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Excluded due to insufficient enrollment 
-101,912 
703,195 
-39,077 
519,409 
-53,978 
2,682,197 
Excluded due to prior use of referent 
-347,539 
355,656 
-307,198 
212,211 
-1,789,291 
892,906 
Excluded due to prior use of exposure and because patient 
qualified in >1 exposure category 
-254,675 
100,981 
-137,453 
74,763 
-554,606 
338,300 
Excluded based on Age 
0 
100,981 
0 
74,758 
-104 
338,196 
Excluded based on Gender 
0 
100,981 
0 
74,758 
0 
338,196 
Excluded based on Use of other NOACs (rivaroxaban, 
dabigatran, edoxaban) 
-5,094 
95,887 
-3118 
71,640 
-19004 
319,192 
Excluded based on Inclusion # 3a - Acute Symptomatic Proximal 
DVT 
-82,653 
13,234 
-60406 
11,234 
-277,170 
42,022 
Excluded based on Inclusion # 3b - Acute Symptomatic PE and 
based on Inclusion # 4 - Age 
-4,641 
8,593 
-2852 
8,382 
-21,229 
20,793 
Excluded based on Exclusion # 1 - pregnancy 
-14 
8,579 
-42 
8,340 
-22 
20,771 
Excluded based on Exclusion # 6 - Thrombectomy, Insertion of 
Caval Filter, or Use of Fibrinolytic Agent 
-211 
8,368 
-143 
8,197 
-24 
20,747 
Excluded based on Exclusion # 7 - Active bleeding (HAS_BLED 
Score >=3), based on Exclusion # 10A - Mechanical Valve, and 
based on Exclusion # 11.1 - Intracranial Bleeding 
-3,708 
4,660 
-1447 
6,750 
-11,558 
9,189 
Excluded based on Exclusion # 11.2 - Intraocular Bleeding 
0 
4,660 
0 
6,750 
0 
9,189 
Excluded based on Exclusion # 11.3 - Gastrointestinal Bleeding 
-12 
4,648 
-52 
6,698 
-78 
9,111 
Excluded based on Exclusion # 11.4 - Head Trauma or Other 
Major Trauma 
-60 
4,588 
-65 
6,633 
-96 
9,015 
Excluded based on Exclusion # 11.5 - Major Surgery, Exclusion # 
11.6 - Ischemic Stroke, Exclusion # 11.7 – Neurosurgery, 
Exclusion # 11.8 - Gross Hematuria, Exclusion # 11.9 - Non - 
healing surgical wound, Exclusion # 11.10 - Intracranial 
neoplasm, arteriovenous malformation or aneurysm, and 
Exclusion # 11.11 - Overt Major Bleeding 
-57 
4,531 
-33 
6,600 
-111 
8,904 
Excluded based on Exclusion # 11.12 - Coagulation defects or 
malignant neoplasm of tissue 
-36 
4,495 
-20 
6,580 
-33 
8,871 
Excluded based on Exclusion # 12 - active liver disease 
-133 
4,362 
-142 
6,438 
-226 
8,645 
Excluded based on Exclusion # 13 - CCI >= 10 and based on 
Exclusion # 14 - Bacterial Endocarditis 
-39 
4,323 
-33 
6,405 
-28 
8,617 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Excluded based on Exclusion # 15 - Uncontrolled Hypertension 
and based on Exclusion # 16 - thrombocytopenia 
-26 
4,297 
-36 
6,369 
-78 
8,539 
Excluded based on Exclusion # 17 – anemia, Exclusion # 18 - 
CKD/ESRD, and Exclusion # 22 - Heparin-induced 
thrombocytopenia 
-33 
4,264 
-31 
6,338 
-139 
8,400 
Excluded based on Exclusion # 27 - aspirin (ASA) >165 mg 
0 
4,264 
0 
6,338 
0 
8,400 
Excluded based on Exclusion # 28 - ASA plus clopidogrel or ASA 
plus ticlopidine 
0 
4,264 
0 
6,338 
0 
8,400 
Final cohort 
 
4,264 
 
6,338 
 
8,400 
 
 
6. Variables  
 
6.1 Exposure-related variables:  
 
Study drug:  
The study exposure of interest is initiation of apixaban. New initiation will be defined by no use of apixaban or warfarin in the prior 6 
months before treatment initiation (washout period). 
 
Comparator: 
New initiators of warfarin, defined by no use of apixaban or warfarin in the prior 6 months. 
 
6.2 Covariates: 
• Age 
• Sex 
• Combined Comorbidity Index (CCI), measured over the baseline covariate assessment period, defined as 180 days prior to 
and including index date 
 
Covariates listed above represent only a small subset of covariates that will ultimately be controlled for in the design and 
analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap 
between treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the 
initial feasibility analysis and the initial power assessment and are listed in Table 1 (Appendix B).  

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
6.3 Outcome variables and study follow-up:  
 
6.3.1 Outcome variables 
 
Primary Effectiveness outcomes of interest: (definitions provided in Appendix A): 
 
• Primary Outcome: VTE and cause-specific mortality 
• Secondary Outcome: Individual components 
o Hospital admission for VTE (principal diagnosis position) 
o Cause-specific mortality 
§ Inpatient mortality identified using discharge status codes from hospitalization for VTE 
 
Safety outcome of interest:  
1. Major bleeding 
 
 
6.3.2 Study follow-up 
Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on the day of 
cohort entry. Because adherence in the real-world databases is expected to be much worse than in the trial, the AT analysis is the 
primary analysis, as it targets the relative hazard of outcomes on treatment.  
 
For the AT analyses, the follow-up will start the day after initiation of apixaban and comparator and will continue until the earliest 
date of the following events: 
• The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,  
• The date of end of continuous registration in the database, 
• End of the study period, 
• Measured death event occurs, 
• Nursing home admission 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
o Nursing home admissions are considered a censoring event because the data sources utilized typically provide little to 
no data on a patient, particularly on drug utilization, after admission. We will utilize this as an exclusion reason for 
cohorts for the same reason. 
• The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug (apixaban 
and comparator) plus a defined grace period (i.e., 10 days after the end of the last prescription’s days’ supply in main 
analyses). 
• The date of augmentation or switching from exposure to comparator or vice versa or augmentation/switching to any other 
NOAC (e.g. switching from apixaban to rivaroxaban would be a censoring event); 
o A dosage change on the index treatment does not fulfill this criterion 
o An added treatment that is not part of the exposure or comparator group does not fulfill this criterion  
• Treatment of current episode of VTE with thrombectomy, insertion of caval filter, or use of fibrinolytic agent (streptokinase, 
alteplase, reteplase, tenecteplase) 
 
 
For the intention-to-treat (ITT) analyses, the censoring based on the augmentation/switching and treatment discontinuation 
will be replaced with a maximum allowed follow-up time of 365 days.  
 
7. Initial Feasibility Analysis  
Aetion report name: 
For apixaban vs. warfarin  
Optum- https://bwh-dope.aetion.com/projects/details/1484/results/64537/result/0  
Marketscan- https://bwh-dope.aetion.com/projects/details/1481/results/64536/result/0  
Medicare- https://bwh-dope.aetion.com/projects/details/1483/results/64535/result/0  
 
Date conducted: 1/19/21 
 
 
Complete Aetion feasibility analysis using age, sex, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the 
outcome. No measures of association will be computed nor will incidence rates stratified by treatment group. 
 
• Report patient characteristics by treatment group 
• Report summary parameters of study population 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
• Report median follow-up time by treatment group 
• Report reasons for censoring in the overall study population 
 
8. Initial Power Assessment 
Aetion report name: 
For apixaban vs. warfarin 
Optum- https://bwh-dope.aetion.com/projects/details/1484/results/64538/result/0  
Marketscan- https://bwh-dope.aetion.com/projects/details/1481/results/64539/result/0  
Medicare- https://bwh-dope.aetion.com/projects/details/1483/results/64540/result/0  
 
Date conducted:  1/19/2021 
In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. 
Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined 
comorbidity index. Power calculations are based on the formulas from Chow et al. (2008). 
 
• Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the 
analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons 
for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and 
reported in the subsequent sections, after incorporating feedback and refining the protocol. 
 
• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of 
advisory board. 
 
Reviewed by PI: 
Jessica Franklin 
Date reviewed: 
11/18/2020 
Reviewed by FDA: 
Ken Quinto 
Date reviewed: 
11/29/2020 
Reasons for stopping 
analysis (if required): 
 
 
9. Balance Assessment 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Aetion report links: 
Optum: https://bwh-dope.aetion.com/projects/details/1484/results/64541/result/0  
Marketscan: https://bwh-dope.aetion.com/projects/details/1481/results/64542/result/0  
Medicare: https://bwh-dope.aetion.com/projects/details/1483/results/64543/result/0  
 
Date conducted: 1/19/2021 
 
After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using the 
dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete 
list of covariates. 
• Provide plot of PS distributions stratified by treatment group. 
 
Note- Please refer to Appendix B.  
 
• Report covariate balance after matching. 
 
Note- For Table 1, please refer to Appendix B.  
 
 
 
 
 
 
 
 
 
 
• Report reasons for censoring by treatment group. 
 
Overall 
Referent 
Exposure 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Dummy outcome 
67 (0.94%) 
25 (0.70%) 
42 (1.18%) 
Death 
103 (1.44%) 
49 (1.37%) 
54 (1.51%) 
Start of an additional exposure 
232 (3.25%) 
175 (4.90%) 
57 (1.60%) 
End of index exposure 
4,701 (65.84%) 
2,202 (61.68%) 
2,499 (70.00%) 
Specified date reached 
857 (12.00%) 
424 (11.88%) 
433 (12.13%) 
End of patient enrollment 
425 (5.95%) 
198 (5.55%) 
227 (6.36%) 
Switch to NOACs (for censoring) + nursing home 
admission + thrombectomy, insertion of caval filter, 
use of fibrinolytic agent 
755 (10.57%) 
497 (13.92%) 
258 (7.23%) 
 
• Report follow-up time by treatment group. 
Median Follow-Up Time (Days) [IQR] 
Patient Group 
Optum 
Marketscan 
Medicare 
Overall Patient Population 
82.5 [38-174.5] 
96 [38-186] 
74 [38-170] 
Referent 
72 [37-189] 
88 [38-171] 
73 [38-161] 
Exposure 
96.5 [38-155] 
100 [38-195] 
78 [38-183] 
 
• Report overall risk of the primary outcome. 
 
Optum 
Marketscan Medicare Pooled 
Risk per 1,000 patients 
12.93 
13.13 
14.66 
13.74 
 
 
10. Final Power Assessment 
 
Date conducted: 12/16/20 
• Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. 
All other parameters in the table should be the same as in Section 8. 
 
o Pooled 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
o Optum 
Non-inferiority Analysis
Number of patients matched
7,140
Reference
3,570
Exposed
3,570
Risk per 1,000 patients
13.74
HR from RCT
0.84
Alpha (2-sided)
0.05
Non-inferiority margin
1.8
Number of events expected
98.1036
Power
0.965194245

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
o Marketscan 
 
 
Non-inferiority Analysis
Number of patients matched
980
Reference
490
Exposed
490
Risk per 1,000 patients
12.93
HR from RCT
0.84
Alpha (2-sided)
0.05
Non-inferiority margin
1.8
Number of events expected
12.6714
Power
0.273097221
Non-inferiority Analysis
Number of patients matched
2,762
Reference
1,381
Exposed
1,381
Risk per 1,000 patients
13.13
Assumed HR from RCT
0.84
Alpha (2-sided)
0.05
Non-inferiority margin
1.8
Number of events expected
36.26506
Power
0.631133873

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
o Medicare 
 
 
• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of 
advisory board. 
Reviewed by PI: 
Shirley Wang 
Date reviewed: 
12/24/2020 
Reviewed by FDA: 
Ken Quinto 
Date reviewed: 
01/18/2020 
Reasons for stopping 
analysis (if required): 
 
 
11. Study Confidence and Concerns 
 
Deadline for voting on study confidence and listing concerns: 
Date votes and concerns are summarized:    
 
• If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps. 
• All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the 
success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may 
Non-inferiority Analysis
Number of patients matched
3,398
Reference
1,699
Exposed
1,699
Risk per 1,000 patients
14.66
Assumed HR from RCT
0.84
Alpha (2-sided)
0.05
Non-inferiority margin
1.8
Number of events expected
49.81468
Power
0.767185633

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study 
variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the 
individual respondent. 
• After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here. 
 
12. Register study protocol on clinicalTrials.gov 
 
Date conducted:    
 
• Register the study on clinicalTrials.gov and upload this document. 
 
13. Comparative Analyses 
 
Aetion report name: 
Date conducted:    
 
13.1 
For primary analysis:  
 
13.2 
For sensitivity analyses: 
 
 
14.  Requested Results  
 
14.1 
Table 1: Baseline characteristics before and after adjustment 
 
Variable 
 
Before adjustment 
After adjustment 
Referent 
Exposure 
Std. diff. 
Referent 
Exposure 
Std. diff. 
Number of patients 
 
 
- 
 
 
- 
Age categories 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
14.2 
Table 2: Follow-up time 
 
Patient Group 
Median Follow-Up Time (Days) [IQR] 
Overall Patient Population 
 
Referent 
 
Exposure 
 
 
14.3 
Table 3: Censoring events 
 
 
Overall 
Referent 
Exposure 
Outcome 
 
 
 
Death 
 
 
 
Start of an additional exposure 
 
 
 
End of index exposure 
 
 
 
Specified date reached 
 
 
 
End of patient data 
 
 
 
End of patient enrollment 
 
 
 
… 
 
 
 
 
14.4 
Table 4: Results from primary analyses; 
 
Analysis 
No. exposed events 
No. referent events 
Exposed rate 
Referent rate 
HR (95% CI) 
Crude 
 
 
 
 
 
Analysis 1 
 
 
 
 
 
Analysis 2 
 
 
 
 
 
... 
 
 
 
 
 
HR, Hazard Ratio; CI, Confidence Interval. 
 
14.5 
Table 5: Results from secondary analyses; 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
15. References 
 
Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2013; 
369:799-808.  
 
Chow S, Shao J, Wang H. 2008.  Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 
177 
 
 

AMPLIFY trial definitions 
Implementation in routine care
References/Rationale
Color coding
Apixaban (dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) verus 
conventional therapy (subcutaneous enoxaparin, followed by warfarin)
Apixaban vs. Warfarin
Criteria
Can be replicated in claims
The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to 
venous thromboembolism. 
Measured 1 day after drug initiation
Venous thromboembolism: 
See 'VTE' sheet for codes
Fang MC, Fan D, Sung SH, et al. Validity of Using Inpatient and Outpatient Administrative Codes to 
Identify Acute Venous Thromboembolism: The CVRN VTE Study. Med Care. 2017;55(12):e137-
e143. 
Can be intermediately 
measured in claims
Can't be measured in claims
Signed Written Informed Consent
N/A
Can't be measured in claims 
but not important for the 
analysis
Subjects whose index event was either unprovoked OR provoked with a risk for
recurrence as described in the eligibility checklist
N/A
Either of the following:
• Acute symptomatic proximal deep vein thrombosis (DVT) with evidence of proximal thrombosis that 
involves at least the popliteal vein or a more proximal vein, demonstrated by imaging with: − compression 
ultrasound (CUS), including grey-scale or color-coded Doppler, OR − ascending contrast venography
Measured 180 days prior to and including day of drug initiation in any diagnosis position and in 
an inpatient or ED care setting
Deep vein thrombosis (DVT): 
ICD-9 Dx: 451.xx, 453.xx
ICD-10 Dx: I26.xx, I80.xx, I81.xx, I82.xx, I26.xx
• Acute symptomatic PE with evidence of thrombosis demonstrated by imaging as follows:
− an intraluminal filling defect in segmental or more proximal branches on spiral computed tomography 
(CT) scan; or
− an intraluminal filling defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the 
pulmonary angiogram; or
− a perfusion defect of at least 75% of a segment with a local normal ventilation result (high probability) on 
ventilation/perfusion lung scan (VPLS)
Measured 180 days prior to and including day of drug initiation in any diagnosis position and in 
an inpatient or ED care setting
Pulmonary embolism (PE):
ICD-9 Dx: 415.xx
ICD-10 Dx: I26.xx
Men and women, ages 18 years or greater
Measured at day of drug initiation 
Age >= 18  
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid 
pregnancy  throughout the study in such a manner that the risk of pregnancy is minimized. (Additional 
details in Supplementary Appendix)
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent 
units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of investigational 
product.
WOCBP who are unwilling or unable to use an acceptable method of birth control (such as oral 
contraceptives, other hormonal contraceptives [vaginal products, skin patches, or implanted or injectable 
products], or mechanical products such as an intrauterine device or barrier methods [diaphragm, 
condoms, spermicides]) to avoid pregnancy for the entire study.
Women who are pregnant or breastfeeding.
Women with a positive pregnancy test on enrollment or prior to investigational product administration.
 Subjects with a provoked index event without the existence of a persistent risk factor for recurrence as 
described in the eligibility checklist
N/A
Less than 6 months of anticoagulation planned for the most recent DVT or pulmonary embolism (PE) (index 
event)
N/A
PRIMARY OUTCOME
Measured 180 days prior to and including day of drug initiation in any dignosis position and in 
an inpatient or outpatient care setting
See 'Pregnancy' sheet for codes
N/A
EXCLUSION CRITERIA
Criteria captured as an exclusion criteria in the  Pregnancy measure 
Please see the following Google Drive for further details or any missing information: 
https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV?usp=sharing
ICD-10 codes are not listed in this document because of excel cell size limitations and excessive number of ICD-10 codes. Full 
ICD-10 code lists will be available in the above Google Drive Folder (link above). ICD-9 to ICD-10 code conversions were 
completed using a SAS macro that implements forward/backward mapping based on the CMS ICD-9 to ICD-10 mapping:
 https://www.nber.org/data/icd9-icd-10-cm-and-pcs-crosswalk-general-equivalence-mapping.html
Trial details- Secondary approval, Successful NI with label change
EXPOSURE vs. COMPARISON
INCLUSION CRITERIA
Appendix A 

Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of 
venous thromboembolism (VTE).
Measured 30 days prior and including the day of drug initiation in any diagnosis position in an 
inpatient or ED care setting
Thrombectomy:
CPT codes: 37184, 37185, 37186, 37187, 37188
HCPCS codes:  C1757 
Caval filter: 
CPT codes: 37191, 37192, 37193
HCPCS codes: C1880
Fibrinolytic agent: 
streptokinase, alteplase, reteplase, tenecteplase
Components will act as both exclusion criterion and censoring events
Active bleeding or high risk for bleeding contraindicating treatment with low-molecularweight heparin 
(LMWH) and a vitamin K antagonist (VKA)
Measured 30 days prior to and including the day of drug initiation
HAS-BLED score >=3 
Major bleeding risk 5.8% per year for score 3
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407886/
Subjects with cancer who will be treated for 6 months or more with LMWH therapy
N/A
Subjects with contraindications according to the local prescribing information of enoxaparin or warfarin
N/A
Subjects with an indication, other than VTE, intended for long-term treatment with a VKA such as:
N/A
Mechanical valve
Measured 180 days prior to and including the drug initiation in any diagnosis position and in 
an inpatient or outpatient care setting
Mechanical valve
ICD-9 Dx: V43.3x
ICD-10 Dx: Z95.2x, Z95.3x, Z95.4x
ICD-9 Px: 35.0x, 35.2x, 35.3x
ICD-10 Px: 02RGxxx, 02RFxxx, 02RHxxx, 02RJxxx, 02QGxxx, 02QFxxx, 02QHxxx, 02QJxxx
 Atrial fibrillation or atrial flutter with moderate to high risk of systemic thromboembolism. Subjects with 
atrial fibrillation that appears to be associated with acute PE may participate.
N/A
Conditions for which serious bleeding may occur and the time of exclusion relative to the time of 
randomization:
 • 6 months
Intracranial bleeding
Measured 180 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient care setting
Intracranial hemorrhage: 
ICD-9 Dx: 430.xx, 431.xx, 432.xx
ICD-10 Dx: I60.xx, I61.xx, I62.xx
Intraocular bleeding
Measured 180 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient care setting
Vitreous hemorrhage:
ICD-9 Dx: 379.23 
ICD-10 Dx: H43.1x  
Retinal hemorrhage 
ICD-9 Dx: 362.81 
ICD-10 Dx: H35.6x, H35.73
Hemophthalmos
ICD-9 Dx: 360.43, 459.0x, 364.41
ICD-10 Dx: H44.8xx
Appendix A 

Gastrointestinal bleeding and/or endoscopically verified ulcer disease
Measured 180 days prior to and including day of drug initiation in any diagnosis position and in 
an inpatient care setting
Gastrointestinal bleeding:
ICD-9 Dx: 
531.0x gastric ulcer w/ hemorrhage, 
531.2x gastric ulcer w/ hemorrhage and perforation 
531.4x
531.6x chronic / unspecified ulcer w/ hemorrhage 
532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x,
534.0x, 534.2x, 534.4x, 534.6x, 562.0x, 562.1x, 568.8x, 569.3x, 569.8x
578.x Gastrointestinal hemorrhage
ICD-10 Dx: 
K25.0x, K25.2x, K25.6x, K26.0x, K26.2x, K26.4x, K26.6x, K27.0x, K27.2x, K27.4x, K27.6x, 
K28.0x, K28.2x, K28.4x, K28.6x, K55.21, K57.xx, K62.5x, K63.1x, K63.81, K66.1x, K92.0x, 
K92.1x, K92.2x
ICD-9 Px: 44.43
ICD-10 Px:  0W3P8ZZ
• 2 months
Head trauma or other major trauma
Measured 60 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient our outpatient care setting 
See 'Major Trauma' sheet for codes
Major surgery
Measured 60 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient or outpatient care setting
Major surgery selected from codes range 35.x- 84.x 
• 1 week
− Ischemic stroke
Measured 7 days prior to and inluding the day of drug initiation in any diagnosis position and 
in an inpatient care setting
Ischemic stroke: 
ICD-9 Dx: 433.x, 434. x, 436.xx
− Neurosurgery
Measured 7 days prior to and including the day of drug initiation in any diagnosis position and 
in an inpatient care setting
Neurosurgery:
ICD-9 Px: 
01.xx, 02.xx, 03.xx, 04.xx, 05.xx
ICD-10 Px: 
00xxxx
• Time of randomization
− Gross hematuria
Measured 1 day prior to and including the of drug initiation in any diagnosis position in an 
inpatient or outpatient care setting
Gross hematuria: 
ICD-9 Dx: 599.71 (not 599.7x)
ICD-10 Dx: R31.0
− Evidence of poor healing of a major wound or major trauma
Measured 1 day prior and including the day of drug initiation in any diagnosis position in an 
inpatient or outpatient care setting
Non-healing surgical wound
ICD-9 Dx: 998.33
ICD-10 Dx: T81.33XA
− Planned major surgery
N/A
Appendix A 

− Intracranial neoplasm, arteriovenous malformation or aneurysm
Measured 1 day prior to and including the day of  drug initiation in any diagnosis position and 
in an inpatient or outpatient care setting
Intracranial neoplasm: 
ICD-9 Dx: 239.6x, 191.xx, 225.xx
ICD-10 Dx: D49.6x, C71.x, D33.0x, D33.1x, D33.2x
AV malformation of brain:
ICD-9 Dx: 747.81
ICD-10 Dx: Q28.2x, Q28.3x 
Cerebral aneurysm
ICD-9 Dx: 437.3x
ICD-10 Dx: I67.1x
− Overt major bleeding
Measured 1 day prior and including the day of drug initiation in any diagnosis position and in 
an inpatient or outpatient care setting
See ' Major Bleeding' sheet for codes
− Documented hemorrhagic tendencies or blood dyscrasias
Measured 1 day prior and including the day of drug initiation in any diagnosis position in an 
inpatient or outpatient care setting
Coagulation defects
ICD-9 Dx: 286.x 
ICD-10 Dx: D65.x, D66.x, D67.xx, D68.xx, D69.xx
Malignant Neoplasm Of Lymphatic And Hematopoietic Tissue
ICD-9 Dx: 200.xx to 209.xx
ICD-10 Dx: C81.xx to C96.xx
Active and clinically significant liver disease (eg, hepatorenal syndrome)
Measured 180 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient or oupatient care setting
Liver disease: 
ICD-9 Dx:
070.xx, 570.xx- 573.xx 
456.0x-456.2x, 576.8x, 782.4x, 789.5x 
ICD-9 Px:
39.1x, 42.91 
Hepatorenal syndrome:
ICD-9 Dx: 572.4
ICD-10 Dx : K76.7
Life expectancy <6 months
Measured 180 days prior to drug initiation in any diagnosis position and in an inpatient or 
outpatient care setting
CCI>=10 
Bacterial endocarditis
Measured 180 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient or outpatient care setting
Bacterial endocarditis:
ICD-9 Dx: 421.0x
ICD-10 Dx: I33.0x
Uncontrolled hypertension: systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg; 
(subjects who have a transient, higher blood pressure elevation associated with acute PE [upper limit: 
systolic blood pressure 200 mm Hg or diastolic blood pressure 100 mm Hg] may enter the study;) elevated 
blood pressure that is persistent 1-2 days after the index DVT or PE should be treated according to local 
guidelines.
Measured 180 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient or outpatient care setting
Malignant hypertension: 
ICD-9 Dx: 401.0x 
Hypertensive urgency/ Hypertensive crisis: 
ICD-10 Dx : I16.xx 
Platelet count <100,000/mm3
Measured 180 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient or outpatient care setting
Thrombocytopenia:
ICD-9 Dx: 287.3x, 287.4x, 287.5x 
ICD-10 Dx: D69.3x, D69.4x, D69.5x, D69.6x
Appendix A 

Hemoglobin <9 g/dL
Measured 180 days prior to and incuding the day of  drug initiation in any diagnosis position 
and in an inpatient or outpatient care setting
Anemia:
ICD 9 Dx:
282.x (hereditary hemolytic anemias)
283.x (acquired hemolytic anemias, autoimmune etc) 
284.x (aplastic anemia and other bone marrow failure syndromes)
Serum creatinine >2.5 mg/dL (221 umol/L)
Calculated creatinine clearance <25 ml/min
ALT or AST >2 times upper limit of normal
Total bilirubin >1.5 times upper limit of normal (unless an alternative causative factor is identified [eg, 
Gilbert’s syndrome]).
Heparin-induced thrombocytopenia;
Measured 180 days prior to and including the day of drug initiation in any position and in an 
inpatient or outpatient care setting
Heparin induced thrombocytopenia (HIT) 
ICD-9 Dx: 289.84
ICD-10 Dx: D75.82
Allergic reaction to unfractionated heparin, LMWH, fondaparinux, or any VKA.
N/A
DVT or PE treatment with more than two doses of fondaparinux or a LMWH that is labeled for once-daily 
dosing, or more than three doses of a LMWH that is labeled for twice-daily dosing, or continuous infusion of 
unfractionated heparin for more than 36 hours, before the first administration of study drug; and/or -- 
N/A
DVT or PE treatment with more than two doses of oral VKA therapy before the first administration of study 
drug.
N/A
Treatment with apixaban in a previous clinical trial.
N/A
Subjects requiring aspirin (ASA) >165 mg/day at randomization.
Measured 1 day prior to and including  the day of drug initiation in any diagnosis position and 
in an inpatient our outpatient care setting
Aspirin (prescription only)
dose greater than >165 mg
Subjects requiring dual antiplatelet therapy (ASA plus clopidogrel or ASA plus ticlopidine) at 
randomization. Subjects who transition from dual antiplatelet therapy to monotherapy prior to 
randomization will be eligible for the trial.
Measured 1 day prior to and including the day of drug initiation in any diagnosis position and 
in an inpatient or outpatient care setting
(both concurrent prescription and combination products)
Aspirin + clopidogrel 
or
Aspirin + ticlopidine
Prisoners or subjects who are involuntarily incarcerated
N/A
Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious 
disease) illness
N/A
Receiving concurrent investigational agents or has received an investigational agent within the past 30 days 
prior to the first dose of study treatment (with the exception of approved medications being used for an 
approved indication, eg, investigating a new dosing regimen for an approved indication)
N/A
Any condition, which in the opinion of the investigator, would put the subject at an unacceptable risk from 
participating in the study
N/A
Any other medical, social, logistical, or psychological reason, which in the opinion of the investigator, 
would preclude compliance with, or successful completion of, the study protocol.
N/A
N/A
(Incorporated into moderate/severe liver disease above)
Measured 180 days prior to and including the day of drug initiation in any diagnosis position 
and in an inpatient or an outpatient care setting
CKD, ESRD: 
ICD-9 Dx: 
585.4x, 585.5x, 585.6x: CKD 4, 5, ESRD
586.xx: renal failure
ICD-10 Dx:
N19.xx
N18.4x Chronic kidney disease, stage 4 (severe)
N18.5x Chronic kidney disease, stage 5
N18.6x End stage renal disease
N18.9x Chronic kidney disease, unspecified
Appendix A 

Trial ID 
Trial Name (with web links)
AMPLIFY
Trial Name (with pdf links)
NCT
NCT00643201
Therapeutic Area
Cardiology/Vascular Diseases
Brand Name
Eliquis
Generic Name
Apixaban
Sponsor
Bristol-Myers Squibb
Year
2013
Measurable endpoint
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the 
Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until 
the Intended End of Study Treatment 
Exposure
Apixaban
Comparator
Enoxaparin, Warfarin
Population
Trial finding
HR = 0.84 (95%CI 0.60–1.18)
Notes
No. of Patients
5,395
Non-inferiority margin
HR = 1.8
Assay Sens. Endpoint
Assay Sens. Finding
Power
0.90; With the use of an estimated incidence of the primary efficacy outcome of 3% at 6 months with 
conventional therapy and a noninferiority margin of 1.80 for the relative risk, we calculated that we would 
need to enroll 4094 patients for the study to have 90% power to show the noninferiority of apixaban, at a one-
sided alpha level of 0.025. This sample was increased to 4816 patients to account for up to 15% of patients 
discontinuing treatment early.
Appendix A 

Title
Major Bleeding
ICD-9 Dx 
423
 HEMOPERICARDIUM
430
 SUBARACHNOID HEMORRHAGE
431
 INTRACEREBRAL HEMORRHAGE
432
 NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1
 SUBDURAL HEMORRHAGE
432.9
 UNSPECIFIED INTRACRANIAL HEMORRHAGE
459
 HEMORRHAGE UNSPECIFIED
531
 ACUTE GASTRIC ULCER WITH HEMORRHAGE
531
 ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.01
 ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2
 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.2
 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21
 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.4
 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.4
 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.41
 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6
 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.6
 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.61
 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532
 ACUTE DUODENAL ULCER WITH HEMORRHAGE
532
 ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01
 ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.2
 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.2
 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.21
 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4
 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.4
 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.41
 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.6
 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6
 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.61
 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
Appendix A 

533
 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533
 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01
 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2
 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.2
 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.21
 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4
 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.4
 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.41
 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.6
 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.6
 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.61
 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534
 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534
 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.01
 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.2
 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.2
 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.21
 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.4
 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4
 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.41
 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.6
 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.6
 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.61
 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
562.02
 DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.03
 DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.12
 DIVERTICULOSIS OF COLON WITH HEMORRHAGE
562.13
 DIVERTICULITIS OF COLON WITH HEMORRHAGE
568.81
 HEMOPERITONEUM (NONTRAUMATIC
569.3
 HEMORRHAGE OF RECTUM AND ANUS
569.83
 PERFORATION OF INTESTINE
569.85
 ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
569.86
 DIEULAFOY LESION (HEMORRHAGIC) OF INTESTINE
578
 HEMATEMESIS
578.1
 BLOOD IN STOOL
Appendix A 

578.9
 HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
719.1
 HEMARTHROSIS
719.1
 HEMARTHROSIS SITE UNSPECIFIED
719.11
 HERARTHROSIS INVOLVING SHOULDER REGION
719.12
 HEMARTHORSIS INVOLVING UPPER ARM
719.13
 HEMARTHROSIS INVOLVING FOREARM
719.14
 HEMARTHROSIS INVOLVING HAND
719.15
 HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.16
 HEMARTHROSIS INVOLVING LOWER LEG
719.17
 HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.18
 HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
719.19
 HEMARTHROSIS INVOLVING MULTIPLE SITES
ICD-10 Dx 
I31.2 
 Hemopericardium, not elsewhere classified
I60.00 
 Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01 
 Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.02 
 Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10 
 Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.11 
 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.12 
 Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
I60.2 
 Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.30 
 Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.31 
 Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.32 
 Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.4 
 Nontraumatic subarachnoid hemorrhage from basilar artery
I60.50 
 Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.51 
 Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.52 
 Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6 
 Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.7 
 Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8 
 Other nontraumatic subarachnoid hemorrhage
I60.9 
 Nontraumatic subarachnoid hemorrhage, unspecified
I61.0 
 Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.1 
 Nontraumatic intracerebral hemorrhage in hemisphere, cortical
Appendix A 

I61.2 
 Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3 
 Nontraumatic intracerebral hemorrhage in brain stem
I61.4 
 Nontraumatic intracerebral hemorrhage in cerebellum
I61.5 
 Nontraumatic intracerebral hemorrhage, intraventricular
I61.6 
 Nontraumatic intracerebral hemorrhage, multiple localized
I61.8 
 Other nontraumatic intracerebral hemorrhage
I61.9 
 Nontraumatic intracerebral hemorrhage, unspecified
I62.00 
 Nontraumatic subdural hemorrhage, unspecified
I62.01 
 Nontraumatic acute subdural hemorrhage
I62.02 
 Nontraumatic subacute subdural hemorrhage
I62.03 
 Nontraumatic chronic subdural hemorrhage
I62.1 
 Nontraumatic extradural hemorrhage
I62.9 
 Nontraumatic intracranial hemorrhage, unspecified
K25.0 
 Acute gastric ulcer with hemorrhage
K25.2 
 Acute gastric ulcer with both hemorrhage and perforation
K25.4 
 Chronic or unspecified gastric ulcer with hemorrhage
K25.6 
 Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0 
 Acute duodenal ulcer with hemorrhage
K26.2 
 Acute duodenal ulcer with both hemorrhage and perforation
K26.4 
 Chronic or unspecified duodenal ulcer with hemorrhage
K26.6 
 Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.0 
 Acute peptic ulcer, site unspecified, with hemorrhage
K27.2 
 Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.4 
 Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.6 
 Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0 
 Acute gastrojejunal ulcer with hemorrhage
K28.2 
 Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.4 
 Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6 
 Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K55.21 
 Angiodysplasia of colon with hemorrhage
K56.60 
 Unspecified intestinal obstruction
K57.01 
 Diverticulitis of small intestine with perforation and abscess with bleeding
K57.11 
 Diverticulosis of small intestine without perforation or abscess with bleeding
K57.13 
 Diverticulitis of small intestine without perforation or abscess with bleeding
K57.21 
 Diverticulitis of large intestine with perforation and abscess with bleeding
Appendix A 

K57.31 
 Diverticulosis of large intestine without perforation or abscess with bleeding
K57.33 
 Diverticulitis of large intestine without perforation or abscess with bleeding
K57.41 
 Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.51 
 Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.53 
 Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.81 
 Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91 
 Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K57.93 
 Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5 
 Hemorrhage of anus and rectum
K63.1 
 Perforation of intestine (nontraumatic
K63.81 
 Dieulafoy lesion of intestine
K66.1 
 Hemoperitoneum
K92.0 
 Hematemesis
K92.1 
 Melena
K92.2 
 Gastrointestinal hemorrhage, unspecified
M25.00 
 Hemarthrosis, unspecified joint
M25.011 
 Hemarthrosis, right shoulder
M25.012 
 Hemarthrosis, left shoulder
M25.019 
 Hemarthrosis, unspecified shoulder
M25.021 
 Hemarthrosis, right elbow
M25.022 
 Hemarthrosis, left elbow
M25.029 
 Hemarthrosis, unspecified elbow
M25.031 
 Hemarthrosis, right wrist
M25.032 
 Hemarthrosis, left wrist
M25.039 
 Hemarthrosis, unspecified wrist
M25.041 
 Hemarthrosis, right hand
M25.042 
 Hemarthrosis, left hand
M25.049 
 Hemarthrosis, unspecified hand
M25.051 
 Hemarthrosis, right hip
M25.052 
 Hemarthrosis, left hip
M25.059 
 Hemarthrosis, unspecified hip
M25.061 
 Hemarthrosis, right knee
M25.062 
 Hemarthrosis, left knee
M25.069 
 Hemarthrosis, unspecified knee
M25.071 
 Hemarthrosis, right ankle
Appendix A 

M25.072 
 Hemarthrosis, left ankle
M25.073 
 Hemarthrosis, unspecified ankle
M25.074 
 Hemarthrosis, right foot
M25.075 
 Hemarthrosis, left foot
M25.076 
 Hemarthrosis, unspecified foot
M25.08 
 Hemarthrosis, other specified site
R58 
 Hemorrhage, not elsewhere classified
R31.9
Heaturia, unspecified in inpatient confinement
R31.9
Heaturia, unspecified in inpatient confinement
R04.2
Hemoptysis
R04.9
Hemorrhage from respiratory passages, unspecified
R04.81
Acute idiopathic pulmonary hemorrhage in infants
R04.89
Hemorrhage from other sites in respiratory passages
R31.0
Gross hematuria 
R31.1
Benign essential microscopic hematuria
R31.2
Other microscopic hematuria 
ICD-9 and 10 Px
0W.3P8ZZ 
 Control Bleeding in Gastrointestinal Tract, Via Natural or Artificial Opening Endoscopic
44.43
 ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING
Appendix A 

Pregnancy 
Dx codes 
650   NORMAL DELIVERY
660   OBSTRUCTED LABOR
661   ABNORMALITY OF FORCES OF LABOR
662   LONG LABOR
663   UMBILICAL CORD COMPLICATIONS DURING LABOR AND DELIVERY
664   TRAUMA TO PERINEUM AND VULVA DURING DELIVERY
665   OTHER OBSTETRICAL TRAUMA
667   RETAINED PLACENTA OR MEMBRANES WITHOUT HEMORRHAGE
668   COMPLICATIONS OF THE ADMINISTRATION OF ANESTHETIC OR OTHER SEDATION IN LABOR AND DELIVERY
669.94   UNSPECIFIED COMPLICATION OF LABOR AND DELIVERY POSTPARTUM CONDITION OR COMPLICATION
V24   POSTPARTUM CARE AND EXAMINATION
V24.0   POSTPARTUM CARE AND EXAMINATION IMMEDIATELY AFTER DELIVERY
V24.1   POSTPARTUM CARE AND EXAMINATION OF LACTATING MOTHER
V24.2   ROUTINE POSTPARTUM FOLLOW
V27   OUTCOME OF DELIVERY
V27.0   MOTHER WITH SINGLE LIVEBORN
V27.1   MOTHER WITH SINGLE STILLBORN
V27.2   MOTHER WITH TWINS BOTH LIVEBORN
V27.3   MOTHER WITH TWINS ONE LIVEBORN AND ONE STILLBORN
V27.4   MOTHER WITH TWINS BOTH STILLBORN
V27.5   MOTHER WITH OTHER MULTIPLE BIRTH ALL LIVEBORN
V27.6   MOTHER WITH OTHER MULTIPLE BIRTH SOME LIVEBORN
V27.7   MOTHER WITH OTHER MULTIPLE BIRTH ALL STILLBORN
V27.9   MOTHER WITH UNSPECIFIED OUTCOME OF DELIVERY
Procedure codes 
72.0   LOW FORCEPS OPERATION
72.1   LOW FORCEPS OPERATION WITH EPISIOTOMY
72.2   MID FORCEPS OPERATION
72.21   MID FORCEPS OPERATION WITH EPISIOTOMY
72.29   OTHER MID FORCEPS OPERATION
72.3   HIGH FORCEPS OPERATION
72.31   HIGH FORCEPS OPERATION WITH EPISIOTOMY
72.39   OTHER HIGH FORCEPS OPERATION
Appendix A 

72.4   FORCEPS ROTATION OF FETAL HEAD
72.5   BREECH EXTRACTION
72.51   PARTIAL BREECH EXTRACTION WITH FORCEPS TO AFTERCOMING HEAD
72.52   OTHER PARTIAL BREECH EXTRACTION
72.53   TOTAL BREECH EXTRACTION WITH FORCEPS TO AFTERCOMING HEAD
72.54   OTHER TOTAL BREECH EXTRACTION
72.6   FORCEPS APPLICATION TO AFTERCOMING HEAD
72.7   VACUUM EXTRACTION
72.71   VACUUM EXTRACTION WITH EPISIOTOMY
72.79   OTHER VACUUM EXTRACTION
72.8   OTHER SPECIFIED INSTRUMENTAL DELIVERY
72.9   UNSPECIFIED INSTRUMENTAL DELIVERY
73.0   ARTIFICIAL RUPTURE OF MEMBRANES
73.01   INDUCTION OF LABOR BY ARTIFICIAL RUPTURE OF MEMBRANES
73.09   OTHER ARTIFICIAL RUPTURE OF MEMBRANES
73.1   OTHER SURGICAL INDUCTION OF LABOR
73.2   INTERNAL AND COMBINED VERSION AND EXTRACTION
73.21   INTERNAL AND COMBINED VERSION WITHOUT EXTRACTION
73.22   INTERNAL AND COMBINED VERSION WITH EXTRACTION
73.3   FAILED FORCEPS
73.4   MEDICAL INDUCTION OF LABOR
73.5   MANUALLY ASSISTED DELIVERY
73.51   MANUAL ROTATION OF FETAL HEAD
73.59   OTHER MANUALLY ASSISTED DELIVERY
73.6   EPISIOTOMY
73.8   OPERATIONS ON FETUS TO FACILITATE DELIVERY
73.9   OTHER OPERATIONS ASSISTING DELIVERY
73.91   EXTERNAL VERSION ASSISTING DELIVERY
73.92   REPLACEMENT OF PROLAPSED UMBILICAL CORD
73.93   INCISION OF CERVIX TO ASSIST DELIVERY
73.94   PUBIOTOMY TO ASSIST DELIVERY
73.99   OTHER OPERATIONS ASSISTING DELIVERY
74.0   CLASSICAL CESAREAN SECTION
74.1   LOW CERVICAL CESAREAN SECTION
74.2   EXTRAPERITONEAL CESAREAN SECTION
Appendix A 

74.3   REMOVAL OF EXTRATUBAL ECTOPIC PREGNANCY
74.4   CESAREAN SECTION OF OTHER SPECIFIED TYPE
74.9   CESAREAN SECTION OF UNSPECIFIED TYPE
74.91   HYSTEROTOMY TO TERMINATE PREGNANCY
74.99   OTHER CESAREAN SECTION OF UNSPECIFIED TYPE
75.4   MANUAL REMOVAL OF RETAINED PLACENTA
75.5   REPAIR OF CURRENT OBSTETRIC LACERATION OF UTERUS
75.6   REPAIR OF OTHER CURRENT OBSTETRIC LACERATION
75.7   MANUAL EXPLORATION OF UTERINE CAVITY, POSTPARTUM
75.9   OTHER OBSTETRIC OPERATIONS
Appendix A 

Title
Venous Thromboembolism (VTE)
ICD-9 Dx inpatient primary position
PE
415.1
 PULMONARY EMBOLISM AND INFARCTION
415.11
 IATROGENIC PULMONARY EMBOLISM AND INFARCTION
415.19
 OTHER PULMONARY EMBOLISM AND INFARCTION
DVT
451.1
 PHLEBITIS AND THROMBOPHLEBITIS OF DEEP VEINS OF LOWER EXTREMITIES
451.11
 PHLEBITIS AND THROMBOPHLEBITIS OF FEMORAL VEIN (DEEP) (SUPERFICIAL)
451.19
 PHLEBITIS AND THROMBOPHLEBITIS OF OTHER
451.2
 PHLEBITIS AND THROMBOPHLEBITIS OF LOWER EXTREMITIES UNSPECIFIED
451.81
 PHLEBITIS AND THROMBOPHLEBITIS OF ILIAC VEIN
451.9
 PHLEBITIS AND THROMBOPHLEBITIS OF UNSPECIFIED SITE
453
 BUDD-CHIARI SYNDROME
453.1
 THROMBOPHLEBITIS MIGRANS
453.2
 EMBOLISM AND THROMBOSIS OF INFERIOR VENA CAVA
453.4
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF DEEP VESSELS OF LOWER EXTREMITY
453.4
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF UNSPECIFIED DEEP VESSELS OF LOWER EXTREMITY
453.41
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF DEEP VESSELS OF PROXIMAL LOWER EXTREMITY
453.42
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF DEEP VESSELS OF DISTAL LOWER EXTREMITY
453.5
 CHRONIC VENOUS EMBOLISM AND THROMBOSIS OF DEEP VESSELS OF LOWER EXTREMITY
453.5
 CHRONIC VENOUS EMBOLISM AND THROMBOSIS OF UNSPECIFIED DEEP VESSELS OF LOWER EXTREMITY
453.51
 CHRONIC VENOUS EMBOLISM AND THROMBOSIS OF DEEP VESSELS OF PROXIMAL LOWER EXTREMITY
453.52
 CHRONIC VENOUS EMBOLISM AND THROMBOSIS OF DEEP VESSELS OF DISTAL LOWER EXTREMITY
453.8
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF OTHER SPECIFIED VEINS
453.82
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF DEEP VEINS OF UPPER EXTREMITY
453.83
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF UPPER EXTREMITY UNSPECIFIED
453.84
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF AXILLARY VEINS
453.85
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF SUBCLAVIAN VEINS
453.86
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF INTERNAL JUGULAR VEINS
453.87
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF OTHER THORACIC VEINS
453.89
 ACUTE VENOUS EMBOLISM AND THROMBOSIS OF OTHER SPECIFIED VEINS
Appendix A 

453.9
 EMBOLISM AND THROMBOSIS OF UNSPECIFIED SITE
ICD-10 Dx inpatient primary position
PE
I26.0 
 Pulmonary embolism with acute cor pulmonale
I26.01 
 Septic pulmonary embolism with acute cor pulmonale
I26.02 
 Saddle embolus of pulmonary artery with acute cor pulmonale
I26.09 
 Other pulmonary embolism with acute cor pulmonale
I26.9 
 Pulmonary embolism without acute cor pulmonale
I26.99 
 Other pulmonary embolism without acute cor pulmonale
DVT
I80.1 
 Phlebitis and thrombophlebitis of femoral vein
I80.10 
 Phlebitis and thrombophlebitis of unspecified femoral vein
I80.11 
 Phlebitis and thrombophlebitis of right femoral vein
I80.12 
 Phlebitis and thrombophlebitis of left femoral vein
I80.13 
 Phlebitis and thrombophlebitis of femoral vein, bilateral
I80.2 
 Phlebitis and thrombophlebitis of other and unspecified deep vessels of lower extremities
I80.20 
 Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities
I80.201 
 Phlebitis and thrombophlebitis of unspecified deep vessels of right lower extremity
I80.202 
 Phlebitis and thrombophlebitis of unspecified deep vessels of left lower extremity
I80.203 
 Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities, bilateral
I80.209 
 Phlebitis and thrombophlebitis of unspecified deep vessels of unspecified lower extremity
I80.21 
 Phlebitis and thrombophlebitis of iliac vein
I80.211 
 Phlebitis and thrombophlebitis of right iliac vein
I80.212 
 Phlebitis and thrombophlebitis of left iliac vein
I80.213 
 Phlebitis and thrombophlebitis of iliac vein, bilateral
I80.219 
 Phlebitis and thrombophlebitis of unspecified iliac vein
I80.22 
 Phlebitis and thrombophlebitis of popliteal vein
I80.221 
 Phlebitis and thrombophlebitis of right popliteal vein
I80.222 
 Phlebitis and thrombophlebitis of left popliteal vein
I80.223 
 Phlebitis and thrombophlebitis of popliteal vein, bilateral
I80.229 
 Phlebitis and thrombophlebitis of unspecified popliteal vein
I80.23 
 Phlebitis and thrombophlebitis of tibial vein
I80.231 
 Phlebitis and thrombophlebitis of right tibial vein
Appendix A 

I80.232 
 Phlebitis and thrombophlebitis of left tibial vein
I80.233 
 Phlebitis and thrombophlebitis of tibial vein, bilateral
I80.239 
 Phlebitis and thrombophlebitis of unspecified tibial vein
I80.29 
 Phlebitis and thrombophlebitis of other deep vessels of lower extremities
I80.291 
 Phlebitis and thrombophlebitis of other deep vessels of right lower extremity
I80.292 
 Phlebitis and thrombophlebitis of other deep vessels of left lower extremity
I80.293 
 Phlebitis and thrombophlebitis of other deep vessels of lower extremity, bilateral
I80.299 
 Phlebitis and thrombophlebitis of other deep vessels of unspecified lower extremity
I80.3 
 Phlebitis and thrombophlebitis of lower extremities, unspecified
I80.9 
 Phlebitis and thrombophlebitis of unspecified site
I82.0 
 Budd-Chiari syndrome
I82.1 
 Thrombophlebitis migrans
I80.3 
 Phlebitis and thrombophlebitis of lower extremities, unspecified
I82.4 
 Acute embolism and thrombosis of deep veins of lower extremity
I82.40 
 Acute embolism and thrombosis of unspecified deep veins of lower extremity
I82.401 
 Acute embolism and thrombosis of unspecified deep veins of right lower extremity
I82.402 
 Acute embolism and thrombosis of unspecified deep veins of left lower extremity
I82.403 
 Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral
I82.409 
 Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity
I82.41 
 Acute embolism and thrombosis of femoral vein
I82.411 
 Acute embolism and thrombosis of right femoral vein
I82.412 
 Acute embolism and thrombosis of left femoral vein
I82.413 
 Acute embolism and thrombosis of femoral vein, bilateral
I82.419 
 Acute embolism and thrombosis of unspecified femoral vein
I82.42 
 Acute embolism and thrombosis of iliac vein
I82.421 
 Acute embolism and thrombosis of right iliac vein
I82.422 
 Acute embolism and thrombosis of left iliac vein
I82.423 
 Acute embolism and thrombosis of iliac vein, bilateral
I82.429 
 Acute embolism and thrombosis of unspecified iliac vein
I82.43 
 Acute embolism and thrombosis of popliteal vein
I82.431 
 Acute embolism and thrombosis of right popliteal vein
I82.432 
 Acute embolism and thrombosis of left popliteal vein
I82.433 
 Acute embolism and thrombosis of popliteal vein, bilateral
I82.439 
 Acute embolism and thrombosis of unspecified popliteal vein
I82.44 
 Acute embolism and thrombosis of tibial vein
Appendix A 

I82.441 
 Acute embolism and thrombosis of right tibial vein
I82.442 
 Acute embolism and thrombosis of left tibial vein
I82.443 
 Acute embolism and thrombosis of tibial vein, bilateral
I82.449 
 Acute embolism and thrombosis of unspecified tibial vein
I82.49 
 Acute embolism and thrombosis of other specified deep vein of lower extremity
I82.491 
 Acute embolism and thrombosis of other specified deep vein of right lower extremity
I82.492 
 Acute embolism and thrombosis of other specified deep vein of left lower extremity
I82.493 
 Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral
I82.499 
 Acute embolism and thrombosis of other specified deep vein of unspecified lower extremity
I82.4Y 
 Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity
I82.4Y1 
 Acute embolism and thrombosis of unspecified deep veins of right proximal lower extremity
I82.4Y2 
 Acute embolism and thrombosis of unspecified deep veins of left proximal lower extremity
I82.4Y3 
 Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral
I82.4Y9 
 Acute embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity
I82.4Z 
 Acute embolism and thrombosis of unspecified deep veins of distal lower extremity
I82.4Z1 
 Acute embolism and thrombosis of unspecified deep veins of right distal lower extremity
I82.4Z2 
 Acute embolism and thrombosis of unspecified deep veins of left distal lower extremity
I82.4Z3 
 Acute embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral
I82.4Z9 
 Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity
I82.5 
 Chronic embolism and thrombosis of deep veins of lower extremity
I82.50 
 Chronic embolism and thrombosis of unspecified deep veins of lower extremity
I82.501 
 Chronic embolism and thrombosis of unspecified deep veins of right lower extremity
I82.502 
 Chronic embolism and thrombosis of unspecified deep veins of left lower extremity
I82.503 
 Chronic embolism and thrombosis of unspecified deep veins of lower extremity, bilateral
I82.509 
 Chronic embolism and thrombosis of unspecified deep veins of unspecified lower extremity
I82.51 
 Chronic embolism and thrombosis of femoral vein
I82.511 
 Chronic embolism and thrombosis of right femoral vein
I82.512 
 Chronic embolism and thrombosis of left femoral vein
I82.513 
 Chronic embolism and thrombosis of femoral vein, bilateral
I82.519 
 Chronic embolism and thrombosis of unspecified femoral vein
I82.52 
 Chronic embolism and thrombosis of iliac vein
I82.521 
 Chronic embolism and thrombosis of right iliac vein
I82.522 
 Chronic embolism and thrombosis of left iliac vein
I82.523 
 Chronic embolism and thrombosis of iliac vein, bilateral
I82.529 
 Chronic embolism and thrombosis of unspecified iliac vein
Appendix A 

I82.53 
 Chronic embolism and thrombosis of popliteal vein
I82.531 
 Chronic embolism and thrombosis of right popliteal vein
I82.532 
 Chronic embolism and thrombosis of left popliteal vein
I82.533 
 Chronic embolism and thrombosis of popliteal vein, bilateral
I82.539 
 Chronic embolism and thrombosis of unspecified popliteal vein
I82.54 
 Chronic embolism and thrombosis of tibial vein
I82.541 
 Chronic embolism and thrombosis of right tibial vein
I82.542 
 Chronic embolism and thrombosis of left tibial vein
I82.543 
 Chronic embolism and thrombosis of tibial vein, bilateral
I82.549 
 Chronic embolism and thrombosis of unspecified tibial vein
I82.59 
 Chronic embolism and thrombosis of other specified deep vein of lower extremity
I82.591 
 Chronic embolism and thrombosis of other specified deep vein of right lower extremity
I82.592 
 Chronic embolism and thrombosis of other specified deep vein of left lower extremity
I82.593 
 Chronic embolism and thrombosis of other specified deep vein of lower extremity, bilateral
I82.599 
 Chronic embolism and thrombosis of other specified deep vein of unspecified lower extremity
I82.5Y 
 Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity
I82.5Y1 
 Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity
I82.5Y2 
 Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity
I82.5Y3 
 Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral
I82.5Y9 
 Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower extremity
I82.5Z 
 Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity
I82.5Z1 
 Chronic embolism and thrombosis of unspecified deep veins of right distal lower extremity
I82.5Z2 
 Chronic embolism and thrombosis of unspecified deep veins of left distal lower extremity
I82.5Z3 
 Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral
I82.5Z9 
 Chronic embolism and thrombosis of unspecified deep veins of unspecified distal lower extremity
I82.6 
 Acute embolism and thrombosis of veins of upper extremity
I82.60 
 Acute embolism and thrombosis of unspecified veins of upper extremity
I82.601 
 Acute embolism and thrombosis of unspecified veins of right upper extremity
I82.602 
 Acute embolism and thrombosis of unspecified veins of left upper extremity
I82.603 
 Acute embolism and thrombosis of unspecified veins of upper extremity, bilateral
I82.609 
 Acute embolism and thrombosis of unspecified veins of unspecified upper extremity
I82.62 
 Acute embolism and thrombosis of deep veins of upper extremity
I82.621 
 Acute embolism and thrombosis of deep veins of right upper extremity
I82.622 
 Acute embolism and thrombosis of deep veins of left upper extremity
I82.623 
 Acute embolism and thrombosis of deep veins of upper extremity, bilateral
Appendix A 

I82.629 
 Acute embolism and thrombosis of deep veins of unspecified upper extremity
I82.890 
 Acute embolism and thrombosis of other specified veins
I82.90 
 Acute embolism and thrombosis of unspecified vein
I82.A1 
 Acute embolism and thrombosis of axillary vein
I82.A11 
 Acute embolism and thrombosis of right axillary vein
I82.A12 
 Acute embolism and thrombosis of left axillary vein
I82.A13 
 Acute embolism and thrombosis of axillary vein, bilateral
I82.A19 
 Acute embolism and thrombosis of unspecified axillary vein
I82.B1 
 Acute embolism and thrombosis of subclavian vein
I82.B11 
 Acute embolism and thrombosis of right subclavian vein
I82.B12 
 Acute embolism and thrombosis of left subclavian vein
I82.B13 
 Acute embolism and thrombosis of subclavian vein, bilateral
I82.B19 
 Acute embolism and thrombosis of unspecified subclavian vein
I82.C1 
 Acute embolism and thrombosis of internal jugular vein
I82.C11 
 Acute embolism and thrombosis of right internal jugular vein
I82.C12 
 Acute embolism and thrombosis of left internal jugular vein
I82.C13 
 Acute embolism and thrombosis of internal jugular vein, bilateral
I82.C19 
 Acute embolism and thrombosis of unspecified internal jugular vein
Appendix A 

AFTER PS MATCHING
BEFORE PS MATCHING
Optum
MarketScan
Medicare
The c-statistics for the propensity score model, pre-matching was 0.938. The postmatching c-statistic 
was 0.684.
The c-statistics for the propensity score model, pre-matching was 0.848. The postmatching c-
statistic was 0.572.
The c-statistics for the propensity score model, pre-matching was 0.874. The postmatching c-statistic 
was 0.566.
Appendix B 

Variable
 Reference - Warfarin 
 Exposure - Apixaban 
St. Diff.
Reference - Warfarin
Exposure - Apixaban
St. Diff.
Reference - Warfarin posure - Apixaban
St. Diff.
 Reference - Warfarin 
 Exposure - Apixaban 
St. Diff.
Number of patients
1,472 
2,783 
2,464
 
3,874
 
4,983
 
3,406
 
8,919 
10,063 
Age
...mean (sd)
56.64 (14.48)
56.04 (14.74)
0.04
51.80 (12.29)
50.99 (12.53)
0.07
62.86 (14.56)
63.42 (13.81)
-0.04
58.78 (13.96)
56.59 (13.60)
0.16
Age categories without zero category
...18 - 54; n (%)
605 (41.1%)
1,207 (43.4%)
-0.05
1,318 (53.5%)
2,133 (55.1%)
-0.03
1,326 (26.6%)
852 (25.0%)
0.04
3,249 (36.4%)
4192 (41.7%)
-0.11
...55 - 64; n (%)
500 (34.0%)
878 (31.5%)
0.05
989 (40.1%)
1,531 (39.5%)
0.01
1,364 (27.4%)
856 (25.1%)
0.05
2,853 (32.0%)
3,265 (32.4%)
-0.01
...65 - 74; n (%)
185 (12.6%)
398 (14.3%)
-0.05
86 (3.5%)
118 (3.0%)
0.03
1,233 (24.7%)
998 (29.3%)
-0.10
1,504 (16.9%)
1,514 (15.0%)
0.05
...>= 75; n (%)
182 (12.4%)
300 (10.8%)
0.05
71 (2.9%)
92 (2.4%)
0.03
1,060 (21.3%)
700 (20.6%)
0.02
1,313 (14.7%)
1,092 (10.9%)
0.11
Gender without zero category- United
...Males; n (%)
747 (50.7%)
1,386 (49.8%)
0.02
1,324 (53.7%)
1,972 (50.9%)
0.06
2,339 (46.9%)
1,571 (46.1%)
0.02
4,410 (49.4%)
4,929 (49.0%)
0.01
...Females; n (%)
725 (49.3%)
1,397 (50.2%)
-0.02
1,140 (46.3%)
1,902 (49.1%)
-0.06
2,644 (53.1%)
1,835 (53.9%)
-0.02
4,509 (50.6%)
5,134 (51.0%)
-0.01
Race 
...White; n (%)
4,106 (82.4%)
2,789 (81.9%)
4,106 (82.4%)
2,789 (81.9%)
0.00
...Black; n (%)
630 (12.6%)
470 (13.8%)
630 (12.6%)
470 (13.8%)
0.00
...Asian; n (%)
24 (0.5%)
13 (0.4%)
24 (0.5%)
13 (0.4%)
0.00
...Hispanic; n (%)
98 (2.0%)
46 (1.4%)
98 (2.0%)
46 (1.4%)
0.00
...North American Native; n (%)
24 (0.5%)
18 (0.5%)
24 (0.5%)
18 (0.5%)
0.00
...Other/Unknown; n (%)
101 (2.0%)
70 (2.1%)
101 (2.0%)
70 (2.1%)
0.00
Region without zero category- United v3 (lumping 
missing&other category with West)
...Northeast; n (%)
156 (10.6%)
262 (9.4%)
0.04
452 (18.3%)
622 (16.1%)
0.06
1,000 (20.1%)
644 (18.9%)
0.03
1608 (18.0%)
1,528 (15.2%)
0.08
...South; n (%)
414 (28.1%)
1,333 (47.9%)
-0.42
749 (30.4%)
869 (22.4%)
0.18
1,368 (27.5%)
1,425 (41.8%)
-0.30
2,531 (28.4%)
3,627 (36.0%)
-0.16
...Midwest; n (%)
503 (34.2%)
658 (23.6%)
0.24
802 (32.5%)
1,978 (51.1%)
-0.38
1,556 (31.2%)
795 (23.3%)
0.18
2,861 (32.1%)
3,431 (34.1%)
-0.04
...West; n (%)
399 (27.1%)
530 (19.0%)
0.19
456 (18.5%)
394 (10.2%)
0.24
1,059 (21.3%)
542 (15.9%)
0.14
1,914 (21.5%)
1,466 (14.6%)
0.18
...Unknown+missing; n (%)
N/A
N/A
#VALUE!
** (0.2%)
** (0.3%)
-0.02
N/A
N/A
#VALUE!
** (0.2%)
** (0.3%)
-0.02
CV Covariates
Ischemic heart disease; n (%)
226 (15.4%)
459 (16.5%)
-0.03
305 (12.4%)
499 (12.9%)
-0.02
968 (19.4%)
714 (21.0%)
-0.04
1,499 (16.8%)
1,672 (16.6%)
0.01
Acute MI; n (%)
67 (4.6%)
123 (4.4%)
0.01
106 (4.3%)
169 (4.4%)
0.00
210 (4.2%)
168 (4.9%)
-0.03
383 (4.3%)
460 (4.6%)
-0.01
ACS/unstable angina; n (%)
40 (2.7%)
99 (3.6%)
-0.05
71 (2.9%)
129 (3.3%)
-0.02
178 (3.6%)
131 (3.8%)
-0.01
289 (3.2%)
359 (3.6%)
-0.02
Old MI; n (%)
36 (2.4%)
72 (2.6%)
-0.01
31 (1.3%)
47 (1.2%)
0.01
269 (5.4%)
171 (5.0%)
0.02
336 (3.8%)
290 (2.9%)
0.05
Stable angina; n (%)
19 (1.3%)
70 (2.5%)
-0.09
27 (1.1%)
82 (2.1%)
-0.08
92 (1.8%)
81 (2.4%)
-0.04
138 (1.5%)
233 (2.3%)
-0.06
Coronary atherosclerosis and other forms of chronic 
ischemic heart disease; n (%)
137 (9.3%)
278 (10.0%)
-0.02
165 (6.7%)
260 (6.7%)
0.00
683 (13.7%)
516 (15.1%)
-0.04
985 (11.0%)
1,054 (10.5%)
0.02
Other atherosclerosis with ICD10 v2 Copy; n (%)
** (0.5%)
12 (0.4%)
0.01
12 (0.5%)
** (0.2%)
0.05
38 (0.8%)
18 (0.5%)
0.04
#VALUE!
#VALUE!
#VALUE!
Previous cardiac procedure (CABG or PTCA or Stent) 
v4; n (%)
** (0.3%)
** (0.1%)
0.04
** (0.2%)
21 (0.5%)
-0.05
20 (0.4%)
13 (0.4%)
0.00
#VALUE!
#VALUE!
#VALUE!
History of CABG or PTCA; n (%)
40 (2.7%)
66 (2.4%)
0.02
19 (0.8%)
32 (0.8%)
0.00
226 (4.5%)
165 (4.8%)
-0.01
285 (3.2%)
263 (2.6%)
0.04
Any stroke; n (%)
** (0.7%)
37 (1.3%)
-0.06
25 (1.0%)
34 (0.9%)
0.01
158 (3.2%)
103 (3.0%)
0.01
#VALUE!
174 (1.7%)
#VALUE!
Ischemic stroke (w and w/o mention of cerebral 
infarction); n (%)
** (0.7%)
37 (1.3%)
-0.06
25 (1.0%)
33 (0.9%)
0.01
146 (2.9%)
100 (2.9%)
0.00
#VALUE!
170 (1.7%)
#VALUE!
Hemorrhagic stroke; n (%)
0 (0.0%)
** (0.1%)
-0.04
0 (0.0%)
** (0.0%)
#DIV/0!
12 (0.2%)
** (0.1%)
0.03
012 (0.1%)
#VALUE!
#VALUE!
TIA; n (%)
** (0.3%)
** (0.4%)
-0.02
** (0.3%)
12 (0.3%)
0.00
44 (0.9%)
19 (0.6%)
0.03
#VALUE!
#VALUE!
#VALUE!
Other cerebrovascular disease; n (%)
** (0.7%)
15 (0.5%)
0.03
20 (0.8%)
22 (0.6%)
0.02
72 (1.4%)
53 (1.6%)
-0.02
#VALUE!
90 (0.9%)
#VALUE!
Cerebrovascular procedure; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.0%)
** (0.0%)
#DIV/0!
#VALUE!
#VALUE!
#VALUE!
Heart failure (CHF); n (%)
145 (9.9%)
273 (9.8%)
0.00
197 (8.0%)
326 (8.4%)
-0.01
805 (16.2%)
506 (14.9%)
0.04
1147 (12.9%)
1,105 (11.0%)
0.06
Peripheral Vascular Disease (PVD) or PVD Surgery v2; 
n (%)
52 (3.5%)
92 (3.3%)
0.01
65 (2.6%)
67 (1.7%)
0.06
315 (6.3%)
206 (6.0%)
0.01
432 (4.8%)
365 (3.6%)
0.06
Atrial fibrillation; n (%)
104 (7.1%)
173 (6.2%)
0.04
131 (5.3%)
247 (6.4%)
-0.05
503 (10.1%)
309 (9.1%)
0.03
738 (8.3%)
729 (7.2%)
0.04
Other cardiac dysrhythmia; n (%)
263 (17.9%)
433 (15.6%)
0.06
409 (16.6%)
635 (16.4%)
0.01
1,028 (20.6%)
668 (19.6%)
0.02
1,700 (19.1%)
1,736 (17.3%)
0.05
Cardiac conduction disorders; n (%)
94 (6.4%)
176 (6.3%)
0.00
136 (5.5%)
169 (4.4%)
0.05
366 (7.3%)
234 (6.9%)
0.02
596 (6.7%)
579 (5.8%)
0.04
Other CVD; n (%)
396 (26.9%)
811 (29.1%)
-0.05
579 (23.5%)
1,035 (26.7%)
-0.07
1,178 (23.6%)
852 (25.0%)
-0.03
2,153 (24.1%)
2,698 (26.8%)
-0.06
Diabetes-related complications
Occurrence of Diabetic Neuropathy v2 Copy; n (%)
31 (2.1%)
123 (4.4%)
-0.13
46 (1.9%)
74 (1.9%)
0.00
291 (5.8%)
154 (4.5%)
0.06
368 (4.1%)
351 (3.5%)
0.03
Occurrence of diabetic nephropathy V3 with ICD10 
Copy; n (%)
21 (1.4%)
51 (1.8%)
-0.03
34 (1.4%)
37 (1.0%)
0.04
110 (2.2%)
51 (1.5%)
0.05
165 (1.8%)
139 (1.4%)
0.03
Hypoglycemia v2; n (%)
** (0.4%)
** (0.1%)
0.06
** (0.3%)
** (0.1%)
0.04
131 (2.6%)
83 (2.4%)
0.01
#VALUE!
#VALUE!
#VALUE!
Hyperglycemia; n (%)
131 (8.9%)
230 (8.3%)
0.02
117 (4.7%)
208 (5.4%)
-0.03
452 (9.1%)
301 (8.8%)
0.01
700 (7.8%)
739 (7.3%)
0.02
Diabetic ketoacidosis; n (%)
** (0.3%)
16 (0.6%)
-0.04
** (0.3%)
19 (0.5%)
-0.03
27 (0.5%)
15 (0.4%)
0.01
#VALUE!
50 (0.5%)
#VALUE!
Hypertension: 1 inpatient or 2 outpatient claims 
within 365 days; n (%)
588 (39.9%)
996 (35.8%)
0.08
974 (39.5%)
1,599 (41.3%)
-0.04
2,258 (45.3%)
1,402 (41.2%)
0.08
3,820 (42.8%)
3,997 (39.7%)
0.06
Hyperlipidemia v2; n (%)
508 (34.5%)
964 (34.6%)
0.00
705 (28.6%)
1,203 (31.1%)
-0.05
1,995 (40.0%)
1,423 (41.8%)
-0.04
3,208 (36.0%)
3,590 (35.7%)
0.01
Edema; n (%)
243 (16.5%)
444 (16.0%)
0.01
335 (13.6%)
550 (14.2%)
-0.02
789 (15.8%)
506 (14.9%)
0.02
1367 (15.3%)
1500 (14.9%)
0.01
Renal Dysfunction (non-diabetic) v2; n (%)
213 (14.5%)
407 (14.6%)
0.00
307 (12.5%)
486 (12.5%)
0.00
916 (18.4%)
580 (17.0%)
0.04
1,436 (16.1%)
1,473 (14.6%)
0.04
Occurrence of acute renal disease v2; n (%)
86 (5.8%)
202 (7.3%)
-0.06
159 (6.5%)
265 (6.8%)
-0.01
513 (10.3%)
284 (8.3%)
0.07
758 (8.5%)
751 (7.5%)
0.04
Occurrence of chronic renal insufficiency; n (%)
87 (5.9%)
124 (4.5%)
0.06
84 (3.4%)
113 (2.9%)
0.03
359 (7.2%)
197 (5.8%)
0.06
530 (5.9%)
434 (4.3%)
0.07
Unmatched
Optum
MarketScan
Medicare
POOLED
Appendix B 

Chronic kidney disease v2; n (%)
80 (5.4%)
116 (4.2%)
0.06
76 (3.1%)
102 (2.6%)
0.03
345 (6.9%)
189 (5.5%)
0.06
501 (5.6%)
407 (4.0%)
0.07
CKD Stage 3-4; n (%)
48 (3.3%)
90 (3.2%)
0.01
56 (2.3%)
75 (1.9%)
0.03
249 (5.0%)
143 (4.2%)
0.04
353 (4.0%)
308 (3.1%)
0.05
Occurrence of hypertensive nephropathy; n (%)
41 (2.8%)
51 (1.8%)
0.07
53 (2.2%)
69 (1.8%)
0.03
213 (4.3%)
98 (2.9%)
0.08
307 (3.4%)
218 (2.2%)
0.07
Occurrence of miscellaneous renal insufficiency v2; n 
(%)
92 (6.2%)
163 (5.9%)
0.01
132 (5.4%)
192 (5.0%)
0.02
326 (6.5%)
229 (6.7%)
-0.01
550 (6.2%)
584 (5.8%)
0.02
Other Covariates
Liver disease; n (%)
** (0.5%)
** (0.1%)
0.07
0 (0.0%)
** (0.1%)
-0.04
28 (0.6%)
** (0.2%)
0.06
#VALUE!
#VALUE!
#VALUE!
Osteoarthritis; n (%)
283 (19.2%)
553 (19.9%)
-0.02
397 (16.1%)
570 (14.7%)
0.04
1,164 (23.4%)
836 (24.5%)
-0.03
1844 (20.7%)
1959 (19.5%)
0.03
Other arthritis, arthropathies and musculoskeletal 
pain; n (%)
868 (59.0%)
1,587 (57.0%)
0.04
1,414 (57.4%)
2,100 (54.2%)
0.06
2,917 (58.5%)
1,938 (56.9%)
0.03
5199 (58.3%)
5625 (55.9%)
0.05
Dorsopathies; n (%)
440 (29.9%)
894 (32.1%)
-0.05
634 (25.7%)
995 (25.7%)
0.00
1,702 (34.2%)
1,139 (33.4%)
0.02
2776 (31.1%)
3028 (30.1%)
0.02
Fractures; n (%)
62 (4.2%)
99 (3.6%)
0.03
78 (3.2%)
114 (2.9%)
0.02
347 (7.0%)
227 (6.7%)
0.01
487 (5.5%)
440 (4.4%)
0.05
Falls v2; n (%)
88 (6.0%)
140 (5.0%)
0.04
47 (1.9%)
98 (2.5%)
-0.04
241 (4.8%)
124 (3.6%)
0.06
376 (4.2%)
362 (3.6%)
0.03
Osteoporosis; n (%)
66 (4.5%)
115 (4.1%)
0.02
53 (2.2%)
68 (1.8%)
0.03
400 (8.0%)
306 (9.0%)
-0.04
519 (5.8%)
489 (4.9%)
0.04
Depression; n (%)
286 (19.4%)
455 (16.3%)
0.08
334 (13.6%)
495 (12.8%)
0.02
1,352 (27.1%)
888 (26.1%)
0.02
1972 (22.1%)
1838 (18.3%)
0.09
Anxiety; n (%)
305 (20.7%)
617 (22.2%)
-0.04
407 (16.5%)
699 (18.0%)
-0.04
1,372 (27.5%)
959 (28.2%)
-0.02
2084 (23.4%)
2275 (22.6%)
0.02
Sleep_Disorder; n (%)
74 (5.0%)
81 (2.9%)
0.11
196 (8.0%)
109 (2.8%)
0.23
376 (7.5%)
105 (3.1%)
0.20
646 (7.2%)
295 (2.9%)
0.20
Dementia; n (%)
73 (5.0%)
136 (4.9%)
0.00
49 (2.0%)
70 (1.8%)
0.01
577 (11.6%)
375 (11.0%)
0.02
699 (7.8%)
581 (5.8%)
0.08
Delirium; n (%)
34 (2.3%)
80 (2.9%)
-0.04
42 (1.7%)
55 (1.4%)
0.02
345 (6.9%)
203 (6.0%)
0.04
421 (4.7%)
338 (3.4%)
0.07
Psychosis; n (%)
25 (1.7%)
51 (1.8%)
-0.01
25 (1.0%)
37 (1.0%)
0.00
418 (8.4%)
305 (9.0%)
-0.02
468 (5.2%)
393 (3.9%)
0.06
Obesity; n (%)
561 (38.1%)
974 (35.0%)
0.06
869 (35.3%)
1,303 (33.6%)
0.04
1,465 (29.4%)
837 (24.6%)
0.11
2895 (32.5%)
3114 (30.9%)
0.03
Overweight; n (%)
64 (4.3%)
193 (6.9%)
-0.11
74 (3.0%)
212 (5.5%)
-0.12
175 (3.5%)
165 (4.8%)
-0.07
313 (3.5%)
570 (5.7%)
-0.11
Smoking; n (%)
538 (36.5%)
1,004 (36.1%)
0.01
444 (18.0%)
742 (19.2%)
-0.03
2,380 (47.8%)
1,651 (48.5%)
-0.01
3362 (37.7%)
3397 (33.8%)
0.08
Alcohol abuse or dependence; n (%)
25 (1.7%)
56 (2.0%)
-0.02
33 (1.3%)
45 (1.2%)
0.01
102 (2.0%)
80 (2.3%)
-0.02
160 (1.8%)
181 (1.8%)
0.00
Drug abuse or dependence; n (%)
75 (5.1%)
163 (5.9%)
-0.04
50 (2.0%)
87 (2.2%)
-0.01
319 (6.4%)
228 (6.7%)
-0.01
444 (5.0%)
478 (4.8%)
0.01
COPD; n (%)
256 (17.4%)
430 (15.5%)
0.05
219 (8.9%)
306 (7.9%)
0.04
1,312 (26.3%)
902 (26.5%)
0.00
1787 (20.0%)
1638 (16.3%)
0.10
Asthma; n (%)
203 (13.8%)
348 (12.5%)
0.04
284 (11.5%)
441 (11.4%)
0.00
773 (15.5%)
484 (14.2%)
0.04
1260 (14.1%)
1273 (12.7%)
0.04
Obstructive sleep apnea; n (%)
261 (17.7%)
405 (14.6%)
0.08
375 (15.2%)
538 (13.9%)
0.04
748 (15.0%)
465 (13.7%)
0.04
1384 (15.5%)
1408 (14.0%)
0.04
Pneumonia; n (%)
258 (17.5%)
513 (18.4%)
-0.02
363 (14.7%)
651 (16.8%)
-0.06
1,074 (21.6%)
748 (22.0%)
-0.01
1695 (19.0%)
1912 (19.0%)
0.00
Other Medications
Use of ACE inhibitors; n (%)
223 (15.1%)
334 (12.0%)
0.09
392 (15.9%)
614 (15.8%)
0.00
751 (15.1%)
437 (12.8%)
0.07
1366 (15.3%)
1385 (13.8%)
0.04
Use of ARBs; n (%)
94 (6.4%)
200 (7.2%)
-0.03
218 (8.8%)
364 (9.4%)
-0.02
233 (4.7%)
163 (4.8%)
0.00
545 (6.1%)
727 (7.2%)
-0.04
Use of Loop Diuretics - United; n (%)
117 (7.9%)
190 (6.8%)
0.04
166 (6.7%)
232 (6.0%)
0.03
677 (13.6%)
383 (11.2%)
0.07
960 (10.8%)
805 (8.0%)
0.10
Use of other diuretics- United; n (%)
34 (2.3%)
60 (2.2%)
0.01
52 (2.1%)
78 (2.0%)
0.01
138 (2.8%)
74 (2.2%)
0.04
224 (2.5%)
212 (2.1%)
0.03
Use of nitrates-United; n (%)
20 (1.4%)
42 (1.5%)
-0.01
33 (1.3%)
43 (1.1%)
0.02
158 (3.2%)
123 (3.6%)
-0.02
211 (2.4%)
208 (2.1%)
0.02
Use of other hypertension drugs; n (%)
33 (2.2%)
69 (2.5%)
-0.02
65 (2.6%)
89 (2.3%)
0.02
235 (4.7%)
147 (4.3%)
0.02
333 (3.7%)
305 (3.0%)
0.04
Use of Anti-arrhythmics; n (%)
16 (1.1%)
34 (1.2%)
-0.01
25 (1.0%)
59 (1.5%)
-0.05
57 (1.1%)
53 (1.6%)
-0.04
98 (1.1%)
146 (1.5%)
-0.04
Use of COPD/asthma meds- United; n (%)
243 (16.5%)
463 (16.6%)
0.00
359 (14.6%)
635 (16.4%)
-0.05
1,077 (21.6%)
815 (23.9%)
-0.05
1679 (18.8%)
1913 (19.0%)
-0.01
Use of statins; n (%)
288 (19.6%)
557 (20.0%)
-0.01
459 (18.6%)
739 (19.1%)
-0.01
1,330 (26.7%)
935 (27.5%)
-0.02
2077 (23.3%)
2231 (22.2%)
0.03
Use of other lipid-lowering drugs; n (%)
47 (3.2%)
95 (3.4%)
-0.01
94 (3.8%)
153 (3.9%)
-0.01
236 (4.7%)
155 (4.6%)
0.00
377 (4.2%)
403 (4.0%)
0.01
Use of antiplatelet agents; n (%)
24 (1.6%)
43 (1.5%)
0.01
53 (2.2%)
92 (2.4%)
-0.01
235 (4.7%)
161 (4.7%)
0.00
312 (3.5%)
296 (2.9%)
0.03
Use of heparin and other low-molecular weight 
heparins; n (%)
840 (57.1%)
122 (4.4%)
1.39
** (0.1%)
** (0.0%)
0.04
2,098 (42.1%)
154 (4.5%)
0.99
#VALUE!
#VALUE!
#VALUE!
Use of NSAIDs; n (%)
156 (10.6%)
344 (12.4%)
-0.06
348 (14.1%)
620 (16.0%)
-0.05
542 (10.9%)
385 (11.3%)
-0.01
1046 (11.7%)
1349 (13.4%)
-0.05
Use of opioids- United; n (%)
589 (40.0%)
1,111 (39.9%)
0.00
1,127 (45.7%)
1,713 (44.2%)
0.03
2,163 (43.4%)
1,464 (43.0%)
0.01
3879 (43.5%)
4288 (42.6%)
0.02
Use of antidepressants; n (%)
385 (26.2%)
715 (25.7%)
0.01
560 (22.7%)
915 (23.6%)
-0.02
1,907 (38.3%)
1,309 (38.4%)
0.00
2852 (32.0%)
2939 (29.2%)
0.06
Use of antipsychotics; n (%)
69 (4.7%)
147 (5.3%)
-0.03
94 (3.8%)
144 (3.7%)
0.01
763 (15.3%)
544 (16.0%)
-0.02
926 (10.4%)
835 (8.3%)
0.07
Labs
3,936 
6,657 
Lab values- HbA1c (%) v3; n (%)
129 (8.8%)
284 (10.2%)
-0.05
** (0.4%)
35 (0.9%)
-0.06
N/A
N/A
#VALUE!
#VALUE!
319 (4.8%)
#VALUE!
Lab values- HbA1c (%) (within 3 months) v3; n (%)
75 (5.1%)
179 (6.4%)
-0.06
** (0.3%)
23 (0.6%)
-0.04
N/A
N/A
#VALUE!
#VALUE!
202 (3.0%)
#VALUE!
Lab values- HbA1c (%) (within 6 months) v3; n (%)
129 (8.8%)
284 (10.2%)
-0.05
** (0.4%)
35 (0.9%)
-0.06
N/A
N/A
#VALUE!
#VALUE!
319 (4.8%)
#VALUE!
Lab values- BNP; n (%)
22 (1.5%)
37 (1.3%)
0.02
0 (0.0%)
** (0.2%)
-0.06
N/A
N/A
#VALUE!
022 (0.6%)
#VALUE!
#VALUE!
Lab values- BNP (within 3 months); n (%)
21 (1.4%)
35 (1.3%)
0.01
0 (0.0%)
** (0.2%)
-0.06
N/A
N/A
#VALUE!
021 (0.5%)
#VALUE!
#VALUE!
Lab values- BNP (within 6 months); n (%)
22 (1.5%)
37 (1.3%)
0.02
0 (0.0%)
** (0.2%)
-0.06
N/A
N/A
#VALUE!
022 (0.6%)
#VALUE!
#VALUE!
Lab values- BUN (mg/dl); n (%)
290 (19.7%)
642 (23.1%)
-0.08
18 (0.7%)
49 (1.3%)
-0.06
N/A
N/A
#VALUE!
308 (7.8%)
691 (10.4%)
-0.09
Lab values- BUN (mg/dl) (within 3 months); n (%)
203 (13.8%)
452 (16.2%)
-0.07
** (0.4%)
32 (0.8%)
-0.05
N/A
N/A
#VALUE!
#VALUE!
484 (7.3%)
#VALUE!
Lab values- BUN (mg/dl) (within 6 months); n (%)
290 (19.7%)
642 (23.1%)
-0.08
18 (0.7%)
49 (1.3%)
-0.06
N/A
N/A
#VALUE!
308 (7.8%)
691 (10.4%)
-0.09
Lab values- Creatinine (mg/dl) v2; n (%)
297 (20.2%)
679 (24.4%)
-0.10
20 (0.8%)
52 (1.3%)
-0.05
N/A
N/A
#VALUE!
317 (8.1%)
731 (11.0%)
-0.10
Lab values- Creatinine (mg/dl) (within 3 months) v2; 
n (%)
206 (14.0%)
483 (17.4%)
-0.09
12 (0.5%)
34 (0.9%)
-0.05
N/A
N/A
#VALUE!
218 (5.5%)
517 (7.8%)
-0.09
Lab values- Creatinine (mg/dl) (within 6 months) v2; 
n (%)
297 (20.2%)
679 (24.4%)
-0.10
20 (0.8%)
52 (1.3%)
-0.05
N/A
N/A
#VALUE!
317 (8.1%)
731 (11.0%)
-0.10
Lab values- HDL level (mg/dl); n (%)
164 (11.1%)
376 (13.5%)
-0.07
12 (0.5%)
37 (1.0%)
-0.06
N/A
N/A
#VALUE!
176 (4.5%)
413 (6.2%)
-0.08
Lab values- HDL level (mg/dl) (within 3 months); n (%)
90 (6.1%)
211 (7.6%)
-0.06
** (0.3%)
23 (0.6%)
-0.04
N/A
N/A
#VALUE!
#VALUE!
234 (3.5%)
#VALUE!
Lab values- HDL level (mg/dl) (within 6 months); n (%)
164 (11.1%)
376 (13.5%)
-0.07
12 (0.5%)
37 (1.0%)
-0.06
N/A
N/A
#VALUE!
176 (4.5%)
413 (6.2%)
-0.08
Lab values- LDL level (mg/dl) v2; n (%)
167 (11.3%)
387 (13.9%)
-0.08
13 (0.5%)
37 (1.0%)
-0.06
N/A
N/A
#VALUE!
180 (4.6%)
424 (6.4%)
-0.08
Appendix B 

Lab values- LDL level (mg/dl) (within 3 months) v2; n 
(%)
91 (6.2%)
217 (7.8%)
-0.06
** (0.3%)
24 (0.6%)
-0.04
N/A
N/A
#VALUE!
#VALUE!
241 (3.6%)
#VALUE!
Lab values- LDL level (mg/dl) (within 6 months) v2; n 
(%)
167 (11.3%)
387 (13.9%)
-0.08
13 (0.5%)
37 (1.0%)
-0.06
N/A
N/A
#VALUE!
180 (4.6%)
424 (6.4%)
-0.08
Lab values- NT-proBNP; n (%)
** (0.6%)
** (0.2%)
0.06
0 (0.0%)
0 (0.0%)
#DIV/0!
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- NT-proBNP (within 3 months); n (%)
** (0.5%)
** (0.1%)
0.07
0 (0.0%)
0 (0.0%)
#DIV/0!
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
-
Lab values- NT-proBNP (within 6 months); n (%)
** (0.6%)
** (0.2%)
0.06
0 (0.0%)
0 (0.0%)
#DIV/0!
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
-
Lab values- Total cholesterol (mg/dl) v2; n (%)
169 (11.5%)
386 (13.9%)
-0.07
** (0.4%)
38 (1.0%)
-0.07
N/A
N/A
#VALUE!
#VALUE!
424 (6.4%)
#VALUE!
Lab values- Total cholesterol (mg/dl) (within 3 
months) v2; n (%)
92 (6.2%)
215 (7.7%)
-0.06
** (0.3%)
24 (0.6%)
-0.04
N/A
N/A
#VALUE!
#VALUE!
239 (3.6%)
#VALUE!
Lab values- Total cholesterol (mg/dl) (within 6 
months) v2; n (%)
169 (11.5%)
386 (13.9%)
-0.07
** (0.4%)
38 (1.0%)
-0.07
N/A
N/A
#VALUE!
#VALUE!
424 (6.4%)
#VALUE!
Lab values- Triglyceride level (mg/dl); n (%)
167 (11.3%)
382 (13.7%)
-0.07
12 (0.5%)
36 (0.9%)
-0.05
N/A
N/A
#VALUE!
179 (4.5%)
418 (6.3%)
-0.08
Lab values- Triglyceride level (mg/dl) (within 3 
months); n (%)
90 (6.1%)
212 (7.6%)
-0.06
** (0.3%)
22 (0.6%)
-0.04
N/A
N/A
#VALUE!
#VALUE!
234 (3.5%)
#VALUE!
Lab values- Triglyceride level (mg/dl) (within 6 
months); n (%)
167 (11.3%)
382 (13.7%)
-0.07
12 (0.5%)
36 (0.9%)
-0.05
N/A
N/A
#VALUE!
179 (4.5%)
418 (6.3%)
-0.08
Lab result number- HbA1c (%) mean (only 2 to 20 
included) v4
129
 
283
 
11
 
35
 
N/A
N/A
140 
318 
...mean (sd)
6.38 (1.65)
6.67 (1.84)
-0.17
7.09 (1.28)
7.19 (1.62)
-0.07
N/A
N/A
#VALUE!
6.44 (1.63)
6.73 (1.82)
-0.17
...Missing; n (%)
1,343 (91.2%)
2,500 (89.8%)
0.05
2,453 (99.6%)
3,839 (99.1%)
0.06
N/A
N/A
#VALUE!
3,796 (96.4%)
6,339 (95.2%)
0.06
Lab result number- BNP mean v2
22
 
37
 
- 
6 
N/A
N/A
22 
43 
...mean (sd)
188.71 (481.48)
211.85 (716.09)
-0.04
- (-)
821.82 (1,746.63)
#VALUE!
N/A
N/A
#VALUE!
#VALUE!
296.96 (918.07)
#VALUE!
...Missing; n (%)
1,450 (98.5%)
2,746 (98.7%)
-0.02
2,464 (100.0%)
3,868 (99.8%)
0.06
N/A
N/A
#VALUE!
3,914 (99.4%)
6,614 (99.4%)
0.00
Lab result number- BUN (mg/dl) mean v2
290 
642 
18 
49 
N/A
N/A
308 
691 
...mean (sd)
14.97 (5.67)
14.75 (4.93)
0.04
11,126.96 (35,122.84)
14.95 (5.16)
0.45
N/A
N/A
#VALUE!
664.37 (8292.09)
14.76 (4.95)
0.11
...Missing; n (%)
1,182 (80.3%)
2,141 (76.9%)
0.08
2,446 (99.3%)
3,825 (98.7%)
0.06
N/A
N/A
#VALUE!
3,628 (92.2%)
5,966 (89.6%)
0.09
Lab result number- Creatinine (mg/dl) mean (only 0.1 
to 15 included) v3
292 
674 
18 
52 
N/A
N/A
310 
726 
...mean (sd)
0.91 (0.29)
0.92 (0.23)
-0.04
1.05 (0.31)
0.95 (0.19)
0.39
N/A
N/A
#VALUE!
0.92 (0.29)
0.92 (0.23)
0.00
...Missing; n (%)
1,180 (80.2%)
2,109 (75.8%)
0.11
2,446 (99.3%)
3,822 (98.7%)
0.06
N/A
N/A
#VALUE!
3,626 (92.1%)
5,931 (89.1%)
0.10
Lab result number- HDL level (mg/dl) mean (only 
=<5000 included) v2
164 
376 
11 
37 
N/A
N/A
175 
413 
...mean (sd)
54.89 (18.99)
49.89 (16.20)
0.28
48.00 (11.92)
42.95 (12.24)
0.42
N/A
N/A
#VALUE!
54.46 (18.71)
49.27 (15.91)
0.30
...Missing; n (%)
1,308 (88.9%)
2,407 (86.5%)
0.07
2,453 (99.6%)
3,837 (99.0%)
0.07
N/A
N/A
#VALUE!
3,761 (95.6%)
6,244 (93.8%)
0.08
Lab result number- LDL level (mg/dl) mean (only 
=<5000 included) v2
164 
385 
11 
34 
N/A
N/A
175 
419 
...mean (sd)
108.72 (37.92)
112.46 (39.24)
-0.10
92.09 (39.78)
94.24 (30.60)
-0.06
N/A
N/A
#VALUE!
107.67 (38.14)
110.98 (38.67)
-0.09
...Missing; n (%)
1,308 (88.9%)
2,398 (86.2%)
0.08
2,453 (99.6%)
3,840 (99.1%)
0.06
N/A
N/A
#VALUE!
3,761 (95.6%)
6,238 (93.7%)
0.08
Lab result number- Total cholesterol (mg/dl) mean 
(only =<5000 included) v2
169 
386 
10 
38 
N/A
N/A
179 
424 
...mean (sd)
191.79 (42.02)
191.77 (43.11)
0.00
176.40 (28.15)
173.63 (53.27)
0.07
N/A
N/A
#VALUE!
190.93 (41.54)
190.14 (44.15)
0.02
...Missing; n (%)
1,303 (88.5%)
2,397 (86.1%)
0.07
2,454 (99.6%)
3,836 (99.0%)
0.07
N/A
N/A
#VALUE!
3,757 (95.5%)
6,233 (93.6%)
0.08
Lab result number- Triglyceride level (mg/dl) mean 
(only =<5000 included) v2
167 
382 
11 
36 
N/A
N/A
178 
418 
...mean (sd)
132.55 (72.17)
147.15 (76.74)
-0.20
163.09 (137.89)
220.01 (535.52)
-0.15
N/A
N/A
#VALUE!
134.44 (77.63)
153.43 (172.03)
-0.14
...Missing; n (%)
1,305 (88.7%)
2,401 (86.3%)
0.07
2,453 (99.6%)
3,838 (99.1%)
0.06
N/A
N/A
#VALUE!
3,758 (95.5%)
6,239 (93.7%)
0.08
Lab result number- Hemoglobin mean (only >0 
included)
255 
568 
13 
41 
N/A
N/A
268 
609 
...mean (sd)
13.68 (1.85)
13.90 (1.82)
-0.12
18,472.91 (45,243.58)
14.22 (1.44)
0.58
N/A
N/A
#VALUE!
909.09 (9627.75)
13.92 (1.80)
0.13
...Missing; n (%)
1,217 (82.7%)
2,215 (79.6%)
0.08
2,451 (99.5%)
3,833 (98.9%)
0.07
N/A
N/A
#VALUE!
3,668 (93.2%)
6,048 (90.9%)
0.09
Lab result number- Serum sodium mean (only > 90 
and < 190 included)
283 
641 
16 
50 
N/A
N/A
299 
691 
...mean (sd)
140.35 (2.52)
140.27 (2.65)
0.03
138.74 (3.71)
139.42 (2.77)
-0.21
N/A
N/A
#VALUE!
140.26 (2.60)
140.21 (2.66)
0.02
...Missing; n (%)
1,189 (80.8%)
2,142 (77.0%)
0.09
2,448 (99.4%)
3,824 (98.7%)
0.07
N/A
N/A
#VALUE!
3,637 (92.4%)
5,966 (89.6%)
0.10
Lab result number- Albumin mean (only >0 and <=10 
included)
254 
602 
14 
41 
N/A
N/A
268 
643 
...mean (sd)
4.05 (0.45)
4.16 (0.37)
-0.27
4.10 (0.28)
4.09 (0.41)
0.03
N/A
N/A
#VALUE!
4.05 (0.44)
4.16 (0.37)
-0.27
...Missing; n (%)
1,218 (82.7%)
2,181 (78.4%)
0.11
2,450 (99.4%)
3,833 (98.9%)
0.05
N/A
N/A
#VALUE!
3,668 (93.2%)
6,014 (90.3%)
0.11
Lab result number- Glucose (fasting or random) mean 
(only 10-1000 included)
282 
638 
17 
52 
N/A
N/A
299 
690 
...mean (sd)
107.08 (33.93)
111.43 (45.57)
-0.11
140.46 (83.78)
142.00 (79.78)
-0.02
N/A
N/A
#VALUE!
108.98 (38.37)
113.73 (48.97)
-0.11
...Missing; n (%)
1,190 (80.8%)
2,145 (77.1%)
0.09
2,447 (99.3%)
3,822 (98.7%)
0.06
N/A
N/A
#VALUE!
3,637 (92.4%)
5,967 (89.6%)
0.10
Lab result number- Potassium mean (only 1-7 
included)
294 
667 
17 
48 
N/A
N/A
311 
715 
...mean (sd)
4.33 (0.42)
4.36 (0.38)
-0.07
4.36 (0.54)
4.28 (0.39)
0.17
N/A
N/A
#VALUE!
4.33 (0.43)
4.35 (0.38)
-0.05
...Missing; n (%)
1,178 (80.0%)
2,116 (76.0%)
0.10
2,447 (99.3%)
3,826 (98.8%)
0.05
N/A
N/A
#VALUE!
3,625 (92.1%)
5,942 (89.3%)
0.10
Comorbidity Scores
Combined comorbidity score, 365 days Copy
...mean (sd)
3.18 (2.27)
3.34 (2.24)
-0.07
2.50 (2.14)
2.91 (2.13)
-0.19
3.69 (2.64)
3.77 (2.52)
-0.03
3.28 (2.45)
3.32 (2.30)
-0.02
Appendix B 

Non-Frailty; n (%)
607 (41.2%)
1,297 (46.6%)
-0.11
986 (40.0%)
1,622 (41.9%)
-0.04
219 (4.4%)
103 (3.0%)
0.07
1,812 (20.3%)
3,022 (30.0%)
-0.22
Frailty Score (mean): Empirical Version 365 days, v2
...mean (sd)
0.17 (0.06)
0.17 (0.06)
0.00
0.16 (0.05)
0.15 (0.05)
0.20
0.10 (0.08)
0.09 (0.07)
0.13
0.13 (0.07)
0.14 (0.06)
-0.15
Healthcare Utilization
Any hospitalization; n (%)
1,342 (91.2%)
2,517 (90.4%)
0.03
2,456 (99.7%)
3,872 (99.9%)
-0.04
4,571 (91.7%)
2,940 (86.3%)
0.17
8,369 (93.8%)
9,329 (92.7%)
0.04
Any hospitalization within prior 30 days; n (%)
1,218 (82.7%)
2,064 (74.2%)
0.21
2,325 (94.4%)
3,266 (84.3%)
0.33
3,605 (72.3%)
2,224 (65.3%)
0.15
7148 (80.1%)
7554 (75.1%)
0.12
Any hospitalization during prior 31-180 days; n (%)
210 (14.3%)
596 (21.4%)
-0.19
279 (11.3%)
830 (21.4%)
-0.28
1,509 (30.3%)
1,094 (32.1%)
-0.04
1998 (22.4%)
2520 (25.0%)
-0.06
Internal medicine/family medicine visits; n (%)
1,258 (85.5%)
2,349 (84.4%)
0.03
1,907 (77.4%)
3,135 (80.9%)
-0.09
4,700 (94.3%)
3,253 (95.5%)
-0.05
7865 (88.2%)
8737 (86.8%)
0.04
Internal medicine/family medicine visits (30 days 
prior) v2; n (%)
1,116 (75.8%)
1,989 (71.5%)
0.10
1,366 (55.4%)
2,291 (59.1%)
-0.07
4,141 (83.1%)
2,772 (81.4%)
0.04
6623 (74.3%)
7052 (70.1%)
0.09
Internal medicine/family medicine visits (31 to 180 
days prior) v2; n (%)
789 (53.6%)
1,532 (55.0%)
-0.03
1,473 (59.8%)
2,428 (62.7%)
-0.06
3,375 (67.7%)
2,384 (70.0%)
-0.05
5637 (63.2%)
6344 (63.0%)
0.00
Cardiologist visit; n (%)
1,070 (72.7%)
2,090 (75.1%)
-0.05
635 (25.8%)
1,120 (28.9%)
-0.07
3,481 (69.9%)
2,461 (72.3%)
-0.05
5186 (58.1%)
5671 (56.4%)
0.03
Number of Cardiologist visits (30 days prior); n (%)
938 (63.7%)
1,782 (64.0%)
-0.01
430 (17.5%)
779 (20.1%)
-0.07
2,604 (52.3%)
1,815 (53.3%)
-0.02
3972 (44.5%)
4376 (43.5%)
0.02
Number of Cardiologist visits (31 to 180 days prior); 
n (%)
283 (19.2%)
629 (22.6%)
-0.08
286 (11.6%)
527 (13.6%)
-0.06
1,509 (30.3%)
1,143 (33.6%)
-0.07
2078 (23.3%)
2299 (22.8%)
0.01
Electrocardiogram v2; n (%)
1,212 (82.3%)
2,366 (85.0%)
-0.07
1,173 (47.6%)
1,921 (49.6%)
-0.04
4,197 (84.2%)
2,949 (86.6%)
-0.07
6582 (73.8%)
7236 (71.9%)
0.04
Use of glucose test strips; n (%)
12 (0.8%)
29 (1.0%)
-0.02
28 (1.1%)
41 (1.1%)
0.00
79 (1.6%)
49 (1.4%)
0.02
119 (1.3%)
119 (1.2%)
0.01
Dialysis; n (%)
0 (0.0%)
** (0.0%)
#DIV/0!
** (0.1%)
** (0.0%)
0.04
** (0.1%)
** (0.1%)
0.00
#VALUE!
#VALUE!
#VALUE!
number of different/distinct medication 
prescriptions
...mean (sd)
7.51 (5.02)
7.40 (5.43)
0.02
7.83 (4.96)
7.62 (5.35)
0.04
9.24 (6.13)
9.03 (6.18)
0.03
8.56 (5.65)
8.04 (5.67)
0.00
Number of Hospitalizations
...mean (sd)
1.06 (0.59)
1.04 (0.59)
0.03
1.15 (0.49)
1.15 (0.46)
0.00
1.26 (0.90)
1.19 (0.91)
0.08
1.20 (0.76)
1.13 (0.68)
0.00
Number of hospital days
...mean (sd)
4.88 (4.21)
3.69 (3.93)
0.29
5.81 (5.06)
4.29 (4.36)
0.32
5.63 (6.19)
4.42 (5.91)
0.20
5.56 (5.60)
4.17 (4.84)
0.00
Number of Emergency Department (ED) visits v3
...mean (sd)
1.67 (2.14)
1.71 (2.26)
-0.02
3.11 (4.52)
3.36 (5.17)
-0.05
2.65 (5.20)
2.69 (4.62)
-0.01
2.62 (4.64)
2.68 (4.35)
0.00
Number of Office visits
...mean (sd)
4.43 (4.31)
4.96 (4.44)
-0.12
4.45 (4.21)
5.00 (4.89)
-0.12
9.79 (12.11)
11.14 (13.34)
-0.11
7.43 (9.48)
7.07 (8.65)
0.00
Number of internal medicine/family medicine visits
...mean (sd)
8.44 (11.38)
8.11 (12.98)
0.03
5.17 (8.34)
5.69 (9.30)
-0.06
11.97 (12.82)
10.87 (11.70)
0.09
9.51 (11.51)
8.11 (11.23)
0.00
Number of Cardiologist visits
...mean (sd)
2.25 (3.08)
2.58 (3.92)
-0.09
0.63 (1.78)
0.78 (2.35)
-0.07
2.57 (4.11)
2.71 (4.05)
-0.03
1.98 (3.45)
1.93 (3.45)
0.00
Number electrocardiograms received v2
...mean (sd)
1.88 (1.87)
2.01 (1.96)
-0.07
0.85 (1.27)
0.91 (1.37)
-0.05
2.23 (2.51)
2.36 (2.62)
-0.05
1.79 (2.13)
1.70 (2.03)
0.00
Number of HbA1c tests ordered
...mean (sd)
0.24 (0.56)
0.27 (0.59)
-0.05
0.20 (0.49)
0.22 (0.53)
-0.04
0.29 (0.63)
0.29 (0.62)
0.00
0.26 (0.58)
0.26 (0.58)
0.00
Number of glucose tests ordered
...mean (sd)
0.10 (0.52)
0.17 (0.82)
-0.10
0.11 (0.91)
0.11 (0.52)
0.00
0.16 (0.58)
0.17 (0.72)
-0.02
0.14 (0.68)
0.15 (0.68)
0.00
Number of lipid tests ordered
...mean (sd)
0.35 (0.62)
0.37 (0.64)
-0.03
0.35 (0.72)
0.36 (0.90)
-0.01
0.34 (0.65)
0.40 (0.65)
-0.09
0.34 (0.67)
0.38 (0.75)
0.00
Total N distinct ICD9/ICD10 diagnoses at the 3rd 
digit level Copy
...mean (sd)
10.10 (11.60)
10.98 (12.08)
-0.07
8.83 (10.24)
10.70 (10.19)
-0.18
15.68 (15.31)
15.80 (15.08)
-0.01
12.87 (13.50)
12.50 (12.54)
0.00
For PS
Hemorrhagic stroke+Other cerebrovascular 
disease+Cerebrovascular procedure (for PS); n (%)
** (0.7%)
17 (0.6%)
0.01
20 (0.8%)
23 (0.6%)
0.02
78 (1.6%)
54 (1.6%)
0.00
#VALUE!
94 (0.9%)
#VALUE!
immobilization; n (%)
37 (2.5%)
73 (2.6%)
#DIV/0!
52 (2.1%)
75 (1.9%)
#DIV/0!
2.01 (1.68)
1.45 (1.21)
52 (2.1%)
75 (1.9%)
0.21
Occurrence of creatinine tests ordered (for PS); n (%)
82 (5.6%)
194 (7.0%)
-0.06
147 (6.0%)
199 (5.1%)
0.04
430 (8.6%)
286 (8.4%)
0.01
659 (7.4%)
679 (6.7%)
0.03
Occurrence of BUN tests ordered (for PS); n (%)
33 (2.2%)
81 (2.9%)
-0.04
76 (3.1%)
103 (2.7%)
0.02
225 (4.5%)
151 (4.4%)
0.00
334 (3.7%)
335 (3.3%)
0.02
Occurrence of chronic renal insufficiency w/o CKD 
(for PS) v2; n (%)
18 (1.2%)
13 (0.5%)
0.08
23 (0.9%)
16 (0.4%)
0.06
102 (2.0%)
32 (0.9%)
0.09
143 (1.6%)
61 (0.6%)
0.10
Chronic kidney disease Stage 1-2 (for PS); n (%)
27 (1.8%)
28 (1.0%)
0.07
18 (0.7%)
29 (0.7%)
0.00
0
0
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Chronic kidney disease Stage 3-6 (for PS); n (%)
48 (3.3%)
90 (3.2%)
0.01
56 (2.3%)
75 (1.9%)
0.03
249 (5.0%)
143 (4.2%)
0.04
353 (4.0%)
308 (3.1%)
0.05
Acute kidney injury; n (%)
86 (5.8%)
204 (7.3%)
#DIV/0!
159 (6.5%)
264 (6.8%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
159 (6.5%)
264 (6.8%)
0.37
Bladder stones+Kidney stones (for PS); n (%)
58 (3.9%)
111 (4.0%)
-0.01
69 (2.8%)
118 (3.0%)
-0.01
177 (3.6%)
117 (3.4%)
0.01
304 (3.4%)
346 (3.4%)
0.00
Alcohol abuse or dependence+Drug abuse or 
dependence (for PS); n (%)
93 (6.3%)
210 (7.5%)
-0.05
77 (3.1%)
126 (3.3%)
-0.01
387 (7.8%)
279 (8.2%)
-0.01
557 (6.2%)
615 (6.1%)
0.00
Other atherosclerosis+Cardiac conduction 
disorders+Other CVD (for PS) v2 Copy; n (%)
459 (31.2%)
916 (32.9%)
-0.04
670 (27.2%)
1,136 (29.3%)
-0.05
1,423 (28.6%)
1,010 (29.7%)
-0.02
2552 (28.6%)
3062 (30.4%)
-0.04
Appendix B 

Previous cardiac procedure (CABG or PTCA or Stent) + 
History of CABG or PTCA (for PS) v3; n (%)
44 (3.0%)
67 (2.4%)
0.04
24 (1.0%)
41 (1.1%)
-0.01
236 (4.7%)
166 (4.9%)
-0.01
304 (3.4%)
274 (2.7%)
0.04
Diabetes with complication; n (%)
61 (4.1%)
193 (6.9%)
#DIV/0!
96 (3.9%)
139 (3.6%)
#DIV/0!
240 (4.8%)
165 (4.8%)
#DIV/0!
96 (3.9%)
139 (3.6%)
0.28
Delirium + Psychosis (for PS); n (%)
56 (3.8%)
123 (4.4%)
-0.03
58 (2.4%)
88 (2.3%)
0.01
681 (13.7%)
456 (13.4%)
0.01
795 (8.9%)
667 (6.6%)
0.09
Any use of Meglitinides (for PS); n (%)
0 (0.0%)
** (0.1%)
-0.04
** (0.1%)
** (0.0%)
0.04
** (0.0%)
** (0.0%)
#DIV/0!
#VALUE!
#VALUE!
#VALUE!
Any use of AGIs (for PS); n (%)
** (0.1%)
** (0.0%)
0.04
** (0.0%)
** (0.0%)
#DIV/0!
** (0.0%)
0 (0.0%)
#DIV/0!
#VALUE!
#VALUE!
#VALUE!
CKD stage 3-6 + dialysis (for PS); n (%)
48 (3.3%)
93 (3.3%)
0.00
58 (2.4%)
77 (2.0%)
0.03
251 (5.0%)
147 (4.3%)
0.03
357 (4.0%)
317 (3.2%)
0.04
Use of thiazide- United; n (%)
80 (5.4%)
111 (4.0%)
0.07
144 (5.8%)
218 (5.6%)
0.01
218 (4.4%)
132 (3.9%)
0.03
442 (5.0%)
461 (4.6%)
0.02
Use of beta blockers; n (%)
204 (13.9%)
361 (13.0%)
0.03
391 (15.9%)
629 (16.2%)
-0.01
933 (18.7%)
556 (16.3%)
0.06
1528 (17.1%)
1546 (15.4%)
0.05
Use of calcium channel blockers; n (%)
151 (10.3%)
283 (10.2%)
0.00
280 (11.4%)
463 (12.0%)
-0.02
507 (10.2%)
305 (9.0%)
0.04
938 (10.5%)
1051 (10.4%)
0.00
All antidiabetic medications except Insulin; n (%)
146 (9.9%)
299 (10.7%)
-0.03
259 (10.5%)
426 (11.0%)
-0.02
620 (12.4%)
405 (11.9%)
0.02
1025 (11.5%)
1130 (11.2%)
0.01
DM Medications - Insulin Copy; n (%)
48 (3.3%)
111 (4.0%)
-0.04
112 (4.5%)
147 (3.8%)
0.04
247 (5.0%)
149 (4.4%)
0.03
407 (4.6%)
407 (4.0%)
0.03
Use of Low Intensity Statins; n (%)
169 (11.5%)
283 (10.2%)
0.04
245 (9.9%)
375 (9.7%)
0.01
788 (15.8%)
546 (16.0%)
-0.01
1202 (13.5%)
1204 (12.0%)
0.04
Use of High Intensity Statins; n (%)
127 (8.6%)
281 (10.1%)
-0.05
216 (8.8%)
380 (9.8%)
-0.03
562 (11.3%)
417 (12.2%)
-0.03
905 (10.1%)
1078 (10.7%)
-0.02
Malignant hypertension; n (%)
** (0.6%)
** (0.1%)
0.08
317 (12.9%)
101 (2.6%)
0.39
517 (10.4%)
93 (2.7%)
0.32
#VALUE!
#VALUE!
#VALUE!
Cardiovascular stress test; n (%)
** (0.7%)
12 (0.4%)
0.04
12 (0.5%)
26 (0.7%)
-0.03
73 (1.5%)
60 (1.8%)
-0.02
#VALUE!
98 (1.0%)
#VALUE!
Echocardiogram; n (%)
909 (61.8%)
1,927 (69.2%)
-0.16
1,573 (63.8%)
2,714 (70.1%)
-0.13
2,941 (59.0%)
2,092 (61.4%)
-0.05
5423 (60.8%)
6733 (66.9%)
-0.13
Number of BNP tests
...mean (sd)
0.14 (0.44)
0.19 (0.52)
-0.10
0.13 (0.44)
0.17 (0.48)
-0.09
0.20 (0.56)
0.23 (0.56)
-0.05
0.17 (0.51)
0.20 (0.52)
-0.06
Number of Cardiac biomarkers tests (tropnin, CK-MBs, Myoglobin, CPK)
...mean (sd)
0.45 (1.21)
0.61 (1.57)
-0.11
0.42 (1.08)
0.50 (1.30)
-0.07
0.41 (0.85)
0.49 (1.00)
-0.09
0.42 (0.98)
0.53 (1.29)
0.00
Number of Ambulatory Blood pressure monitoring tests
...mean (sd)
0.00 (0.00)
0.00 (0.03)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.02)
0.00 (0.02)
0.00
N of days on antihypertensive medications during baseline
0
0
...mean (sd)
37.98 (65.20)
35.77 (64.02)
0.03
43.81 (70.14)
45.02 (70.00)
-0.02
41.02 (66.36)
38.28 (65.03)
0.04
41.29 (67.24)
40.18 (66.72)
0.00
N of days in database anytime prior
0
0
...mean (sd)
1,695.95 (1,337.57)
1,675.11 (1,387.51)
0.02
2,110.22 (1,479.65)
2,106.29 (1,554.62)
0.00
650.58 (464.01)
703.17 (394.05)
-0.12
1226.36 (1010.09)
1512.13 (1231.02)
0.00
Mean Copay for per prescription cost (charges in U.S. $) (180-1 day prior)
0
0
...mean (sd)
22.40 (42.74)
20.39 (46.66)
0.04
11.68 (20.56)
11.08 (17.18)
0.03
110.93 (145.27)
119.78 (325.16)
-0.04
68.90 (110.50)
50.45 (191.05)
0.00
...Missing; n (%)
215 (14.6%)
305 (11.0%)
0.11
296 (12.0%)
380 (9.8%)
0.07
595 (11.9%)
349 (10.2%)
0.05
1106 (12.4%)
1034 (10.3%)
0.07
Colonoscopy; n (%)
45 (3.1%)
102 (3.7%)
-0.03
109 (4.4%)
148 (3.8%)
0.03
131 (2.6%)
105 (3.1%)
-0.03
285 (3.2%)
355 (3.5%)
-0.02
Fecal occult blood (FOB) test; n (%)
44 (3.0%)
53 (1.9%)
0.07
81 (3.3%)
117 (3.0%)
0.02
93 (1.9%)
83 (2.4%)
-0.03
218 (2.4%)
253 (2.5%)
-0.01
Flu vaccine; n (%)
180 (12.2%)
385 (13.8%)
-0.05
243 (9.9%)
376 (9.7%)
0.01
1,351 (27.1%)
881 (25.9%)
0.03
1774 (19.9%)
1642 (16.3%)
0.09
Mammogram; n (%)
139 (9.4%)
279 (10.0%)
-0.02
228 (9.3%)
382 (9.9%)
-0.02
437 (8.8%)
313 (9.2%)
-0.01
804 (9.0%)
974 (9.7%)
-0.02
Pap smear; n (%)
81 (5.5%)
152 (5.5%)
0.00
165 (6.7%)
307 (7.9%)
-0.05
164 (3.3%)
120 (3.5%)
-0.01
410 (4.6%)
579 (5.8%)
-0.05
Pneumonia vaccine; n (%)
254 (17.3%)
595 (21.4%)
-0.10
250 (10.1%)
504 (13.0%)
-0.09
1,373 (27.6%)
1,063 (31.2%)
-0.08
1877 (21.0%)
2162 (21.5%)
-0.01
PSA test or Prostate exam for DRE; n (%)
117 (7.9%)
283 (10.2%)
-0.08
225 (9.1%)
381 (9.8%)
-0.02
379 (7.6%)
313 (9.2%)
-0.06
721 (8.1%)
977 (9.7%)
-0.06
Bone mineral density; n (%)
28 (1.9%)
66 (2.4%)
-0.03
29 (1.2%)
55 (1.4%)
-0.02
133 (2.7%)
136 (4.0%)
-0.07
190 (2.1%)
257 (2.6%)
-0.03
Use of CNS stimulants; n (%)
15 (1.0%)
43 (1.5%)
-0.05
19 (0.8%)
67 (1.7%)
-0.08
40 (0.8%)
28 (0.8%)
0.00
74 (0.8%)
138 (1.4%)
-0.06
Use of estrogens, progestins, androgens; n (%)
151 (10.3%)
309 (11.1%)
-0.03
284 (11.5%)
637 (16.4%)
-0.14
220 (4.4%)
183 (5.4%)
-0.05
655 (7.3%)
1129 (11.2%)
-0.13
Use of Angiogenesis inhibitors; n (%)
** (0.1%)
** (0.0%)
0.04
** (0.0%)
** (0.1%)
-0.04
** (0.1%)
** (0.1%)
0.00
#VALUE!
#VALUE!
#VALUE!
Use of Oral Immunosuppressants; n (%)
** (0.1%)
** (0.2%)
-0.03
13 (0.5%)
** (0.3%)
0.03
12 (0.2%)
** (0.2%)
0.00
#VALUE!
#VALUE!
#VALUE!
Use of fondaparinux or Bivalirudin; n (%)
** (0.2%)
** (0.1%)
0.03
13 (0.5%)
** (0.1%)
0.07
** (0.2%)
** (0.1%)
0.03
#VALUE!
#VALUE!
#VALUE!
Use of other direct thrombin inhibitors (lepirudin, 
desirudin, argatroban); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
Use of Ticagrelor ON CED; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.0%)
** (0.1%)
-0.04
** (0.0%)
** (0.1%)
-0.04
#VALUE!
#VALUE!
#VALUE!
Use of Ticagrelor; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.0%)
** (0.1%)
-0.04
** (0.0%)
** (0.3%)
-0.08
#VALUE!
#VALUE!
#VALUE!
Number of D-dimer tests
...mean (sd)
0.18 (0.45)
0.20 (0.47)
-0.04
0.16 (0.42)
0.19 (0.48)
-0.07
0.18 (0.44)
0.22 (0.50)
-0.08
0.17 (0.44)
0.20 (0.48)
0.00
Numbe of CRP, high-sensitivity CRP tests
...mean (sd)
0.09 (0.43)
0.12 (0.59)
-0.06
0.09 (0.39)
0.11 (0.56)
-0.04
0.12 (0.54)
0.15 (0.58)
-0.05
0.11 (0.49)
0.13 (0.58)
0.00
Number of PT or aPTTt tests
...mean (sd)
1.08 (2.54)
0.67 (1.47)
0.20
0.97 (2.49)
0.63 (1.48)
0.17
1.27 (2.98)
0.42 (0.90)
0.39
1.16 (2.78)
0.57 (1.31)
0.00
Number of Bleeding time tests
...mean (sd)
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.02)
0.00 (0.00)
0.00
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.01)
0.00 (0.00)
0.00
HAS-BLED Score (ICD-9 and ICD-10), 180 days
...mean (sd)
2.01 (0.69)
1.99 (0.71)
0.03
1.88 (0.70)
1.88 (0.68)
0.00
2.34 (0.79)
2.36 (0.77)
-0.03
2.16 (0.75)
2.07 (0.72)
0.00
N of Generic name drugs
...mean (sd)
13.81 (14.14)
12.17 (14.72)
0.11
11.84 (10.98)
10.94 (11.84)
0.08
18.87 (18.89)
17.63 (18.34)
0.07
16.09 (16.30)
13.54 (15.09)
0.00
N of Brand name drugs
...mean (sd)
1.91 (3.43)
3.26 (4.17)
-0.35
2.10 (3.31)
3.10 (3.40)
-0.30
3.01 (5.24)
4.06 (5.03)
-0.20
2.58 (4.51)
3.47 (4.22)
0.00
Use of clopidogrel ; n (%)
12 (0.8%)
** (0.3%)
0.07
18 (0.7%)
16 (0.4%)
0.04
175 (3.5%)
113 (3.3%)
0.01
205 (2.3%)
#VALUE!
#VALUE!
Systemic embolism; n (%)
28 (1.9%)
47 (1.7%)
0.02
52 (2.1%)
73 (1.9%)
0.01
76 (1.5%)
58 (1.7%)
-0.02
156 (1.7%)
178 (1.8%)
-0.01
DVT; n (%)
861 (58.5%)
1,392 (50.0%)
0.17
1,610 (65.3%)
1,981 (51.1%)
0.29
2,794 (56.1%)
1,519 (44.6%)
0.23
5265 (59.0%)
4892 (48.6%)
0.21
Post-thrombotic syndrome; n (%)
0 (0.0%)
** (0.1%)
#DIV/0!
** (0.1%)
** (0.2%)
#DIV/0!
131 (2.6%)
41 (1.2%)
#DIV/0!
** (0.1%)
** (0.2%)
0.04
PE; n (%)
1,472 (100.0%)
2,783 (100.0%)
#DIV/0!
2,457 (99.7%)
3,874 (100.0%)
-0.08
4,964 (99.6%)
3,400 (99.8%)
-0.04
8893 (99.7%)
10057 (99.9%)
-0.04
Coagulation defects; n (%)
28 (1.9%)
42 (1.5%)
#DIV/0!
83 (3.4%)
99 (2.6%)
#DIV/0!
0
0
#DIV/0!
83 (3.4%)
99 (2.6%)
0.27
Diabetes: 1 inpatient or 2 outpatient claims within 
183 days ; n (%)
217 (14.7%)
446 (16.0%)
-0.04
383 (15.5%)
574 (14.8%)
0.02
1,134 (22.8%)
694 (20.4%)
0.06
1734 (19.4%)
1714 (17.0%)
0.06
Appendix B 

Intracranial or retroperitoneal hemorrhage: 1 
inpatient or 2 outpatient claims within 183 days ; n 
(%)
** (0.2%)
** (0.2%)
0.00
** (0.1%)
** (0.1%)
0.00
17 (0.3%)
** (0.2%)
0.02
#VALUE!
#VALUE!
#VALUE!
Peptic Ulcer Disease; n (%)
372 (25.3%)
669 (24.0%)
0.03
442 (17.9%)
777 (20.1%)
-0.06
1,545 (31.0%)
1,080 (31.7%)
-0.02
2359 (26.4%)
2526 (25.1%)
0.03
Upper GI bleed; n (%)
** (0.2%)
** (0.1%)
0.03
** (0.1%)
** (0.1%)
0.00
** (0.1%)
** (0.3%)
-0.04
#VALUE!
#VALUE!
#VALUE!
Lower/ unspecified GI bleed; n (%)
17 (1.2%)
32 (1.1%)
0.01
38 (1.5%)
38 (1.0%)
0.05
59 (1.2%)
36 (1.1%)
0.01
114 (1.3%)
106 (1.1%)
0.02
Urogenital bleed; n (%)
41 (2.8%)
77 (2.8%)
0.00
75 (3.0%)
115 (3.0%)
0.00
137 (2.7%)
92 (2.7%)
0.00
253 (2.8%)
284 (2.8%)
0.00
Other bleeds; n (%)
49 (3.3%)
103 (3.7%)
-0.02
96 (3.9%)
144 (3.7%)
0.01
196 (3.9%)
114 (3.3%)
0.03
341 (3.8%)
361 (3.6%)
0.01
Prior cancer; n (%)
194 (13.2%)
447 (16.1%)
-0.08
279 (11.3%)
511 (13.2%)
-0.06
901 (18.1%)
751 (22.0%)
-0.10
1374 (15.4%)
1709 (17.0%)
-0.04
Antibiotics; n (%)
633 (43.0%)
1,313 (47.2%)
#DIV/0!
1,127 (45.7%)
1,866 (48.2%)
#DIV/0!
899 (18.0%)
523 (15.4%)
#DIV/0!
1,127 (45.7%)
1,866 (48.2%)
1.30
Aspirin; n (%)
** (0.6%)
15 (0.5%)
0.01
24 (1.0%)
50 (1.3%)
-0.03
** (0.1%)
** (0.2%)
-0.03
#VALUE!
#VALUE!
#VALUE!
Aspirin/dipyridamole; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
** (0.0%)
#DIV/0!
** (0.0%)
** (0.1%)
-0.04
#VALUE!
#VALUE!
#VALUE!
Other antiplatelet agents; n (%)
** (0.1%)
** (0.1%)
0.00
** (0.1%)
** (0.1%)
0.00
13 (0.3%)
** (0.2%)
0.02
#VALUE!
#VALUE!
#VALUE!
PGP inhibitors; n (%)
290 (19.7%)
590 (21.2%)
-0.04
512 (20.8%)
842 (21.7%)
-0.02
1,127 (22.6%)
834 (24.5%)
-0.04
1929 (21.6%)
2266 (22.5%)
-0.02
Other gastroprotective agents; n (%)
14 (1.0%)
38 (1.4%)
-0.04
22 (0.9%)
51 (1.3%)
-0.04
94 (1.9%)
57 (1.7%)
0.02
130 (1.5%)
146 (1.5%)
0.00
Number of lipid tests ordered
...mean (sd)
0.35 (0.62)
0.37 (0.64)
-0.03
0.35 (0.72)
0.36 (0.90)
-0.01
0.36 (0.72)
0.42 (0.70)
-0.08
0.36 (0.70)
0.38 (0.77)
0.00
Proton pump inhibitor; n (%)
265 (18.0%)
493 (17.7%)
0.01
416 (16.9%)
666 (17.2%)
-0.01
1,416 (28.4%)
947 (27.8%)
0.01
2097 (23.5%)
2106 (20.9%)
0.06
H2 receptor antagonist; n (%)
48 (3.3%)
74 (2.7%)
0.04
91 (3.7%)
127 (3.3%)
0.02
348 (7.0%)
249 (7.3%)
-0.01
487 (5.5%)
450 (4.5%)
0.05
Vitamin K therapy; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.0%)
** (0.0%)
#DIV/0!
** (0.0%)
0 (0.0%)
#DIV/0!
#VALUE!
#VALUE!
#VALUE!
Number of INR (prothrombin) tests ordered
...mean (sd)
0.84 (2.15)
0.35 (0.80)
0.30
0.76 (2.07)
0.39 (0.86)
0.23
1.24 (2.96)
0.40 (0.86)
0.39
1.04 (2.62)
0.38 (0.84)
0.00
Treating prescriber - Cardiologist; n (%)
950 (64.5%)
1,803 (64.8%)
-0.01
1,503 (61.0%)
2,341 (60.4%)
0.01
2,604 (52.3%)
1,815 (53.3%)
-0.02
5057 (56.7%)
5959 (59.2%)
-0.05
Treating prescriber - Primary Care Physician; n (%)
1,278 (86.8%)
2,280 (81.9%)
0.14
1,112 (45.1%)
1,672 (43.2%)
0.04
1,906 (38.3%)
1,293 (38.0%)
0.01
4296 (48.2%)
5245 (52.1%)
-0.08
Treating prescriber - Other; n (%)
1,449 (98.4%)
2,693 (96.8%)
0.10
2,303 (93.5%)
3,562 (91.9%)
0.06
4,710 (94.5%)
3,212 (94.3%)
0.01
8462 (94.9%)
9467 (94.1%)
0.04
Alpha blockers; n (%)
73 (5.0%)
146 (5.2%)
-0.01
95 (3.9%)
155 (4.0%)
-0.01
373 (7.5%)
278 (8.2%)
-0.03
541 (6.1%)
579 (5.8%)
0.01
CHA2DS2 VASc score, 180 days, V
...mean (sd)
1.73 (1.38)
1.29 (1.12)
0.35
1.73 (1.43)
1.08 (1.06)
0.52
2.01 (1.68)
1.45 (1.21)
0.38
1.89 (1.57)
1.26 (1.13)
0.00
Use of Prasugrel; n (%)
0 (0.0%)
** (0.1%)
-0.04
0 (0.0%)
** (0.1%)
-0.04
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
#VALUE!
#VALUE!
Use of Loop Diuretics+other diuretics+other 
hypertension drugs; n (%)
154 (10.5%)
275 (9.9%)
0.02
241 (9.8%)
344 (8.9%)
0.03
899 (18.0%)
523 (15.4%)
0.07
1294 (14.5%)
1142 (11.3%)
0.10
Commercial vs Medicare Advantage- Business Type 
Code - CORRECT ONE - OPTUM
...Commercial; n (%)
0,857 (58.2%)
1657 (59.5%)
-0.03
0,177 (7.2%)
224 (5.8%)
0.06
-
-
#VALUE!
#VALUE!
1881 (28.3%)
#VALUE!
...Medicare Advantage; n (%)
0,615 (41.8%)
1126 (40.5%)
0.03
2,287 (92.8%)
3650 (94.2%)
-0.06
-
-
#VALUE!
#VALUE!
4776 (71.7%)
#VALUE!
Commercial vs Medicare Advantage- Business Type 
Code
...COM = COMMERCIAL; n (%)
857 (58.2%)
1,657 (59.5%)
-0.03
-
-
-
-
#VALUE!
857 (58.2%)
1,657 (59.5%)
-0.03
...MCR = MEDICARE; n (%)
615 (41.8%)
1,126 (40.5%)
0.03
-
-
-
-
#VALUE!
615 (41.8%)
1,126 (40.5%)
0.03
...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...NONE = NO BUSINESS LINE CODE (added in 2015); n 
(%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- Data Type
...1 - Fee For Service; n (%)
-
-
2,058 (83.5%)
3,291 (85.0%)
-0.04
-
-
2,058 (83.5%)
3,291 (85.0%)
-0.04
...2 - Encounter; n (%)
-
-
229 (9.3%)
359 (9.3%)
0.00
-
-
229 (9.3%)
359 (9.3%)
0.00
...3 - Medicare; n (%)
-
-
157 (6.4%)
204 (5.3%)
0.05
-
-
157 (6.4%)
204 (5.3%)
0.05
...4 - Medicare Encounter; n (%)
-
-
20 (0.8%)
20 (0.5%)
0.04
-
-
20 (0.8%)
20 (0.5%)
0.04
Metropolitan Statistical Area - Urban (any MSA) vs 
Rural (non-MSA)
0
0
0.00
...Urban; n (%)
-
-
1,819 (73.8%)
2,639 (68.1%)
0.13
-
-
1,819 (73.8%)
2,639 (68.1%)
0.13
...Rural; n (%)
-
-
197 (8.0%)
483 (12.5%)
-0.15
-
-
197 (8.0%)
483 (12.5%)
-0.15
...Unknown/Missing; n (%)
-
-
448 (18.2%)
752 (19.4%)
-0.03
-
-
448 (18.2%)
752 (19.4%)
-0.03
Due to CMS cell suppression policy, all values less than 11 are denoted with **
Appendix B 

Variable
Reference - Warfarin
Exposure - Apixaban
St. Diff.
Reference - Warfarin
Exposure - Apixaban
St. Diff.
Reference - Warfarin
Exposure - Apixaban
St. Diff.
 Reference - Warfarin 
 Exposure - Apixaban 
St. Diff.
Number of patients
490
 
490
 
1,381
 
1,381
 
1,699
 
1,699
 
3,570 
3,570 
Age
...mean (sd)
57.18 (14.30)
57.47 (14.12)
-0.02
51.78 (12.29)
51.77 (12.07)
0.00
62.91 (14.58)
62.87 (14.01)
0.00
57.82 (13.70)
57.83 (13.31)
0.00
Age categories without zero category
...18 - 54; n (%)
201 (41.0%)
184 (37.6%)
0.07
726 (52.6%)
748 (54.2%)
-0.03
449 (26.4%)
453 (26.7%)
-0.01
1376 (38.5%)
1385 (38.8%)
-0.01
...55 - 64; n (%)
167 (34.1%)
170 (34.7%)
-0.01
568 (41.1%)
547 (39.6%)
0.03
494 (29.1%)
475 (28.0%)
0.02
1,229 (34.4%)
1,192 (33.4%)
0.02
...65 - 74; n (%)
54 (11.0%)
87 (17.8%)
-0.19
53 (3.8%)
48 (3.5%)
0.02
383 (22.5%)
427 (25.1%)
-0.06
490 (13.7%)
562 (15.7%)
-0.06
...>= 75; n (%)
68 (13.9%)
49 (10.0%)
0.12
34 (2.5%)
38 (2.8%)
-0.02
373 (22.0%)
344 (20.2%)
0.04
475 (13.3%)
431 (12.1%)
0.04
Gender without zero category- United
...Males; n (%)
240 (49.0%)
229 (46.7%)
0.05
727 (52.6%)
709 (51.3%)
0.03
786 (46.3%)
781 (46.0%)
0.01
1,753 (49.1%)
1,719 (48.2%)
0.02
...Females; n (%)
250 (51.0%)
261 (53.3%)
-0.05
654 (47.4%)
672 (48.7%)
-0.03
913 (53.7%)
918 (54.0%)
-0.01
1,817 (50.9%)
1,851 (51.8%)
-0.02
Race 
...White; n (%)
1,373 (80.8%)
1,381 (81.3%)
1,373 (80.8%)
1,381 (81.3%)
0.00
...Black; n (%)
247 (14.5%)
240 (14.1%)
247 (14.5%)
240 (14.1%)
0.00
...Asian; n (%)
** (0.5%)
** (0.4%)
** (0.5%)
** (0.4%)
0.00
...Hispanic; n (%)
34 (2.0%)
33 (1.9%)
34 (2.0%)
33 (1.9%)
0.00
...North American Native; n (%)
** (0.4%)
** (0.6%)
** (0.4%)
** (0.6%)
0.00
...Other/Unknown; n (%)
29 (1.7%)
28 (1.6%)
29 (1.7%)
28 (1.6%)
0.00
Region without zero category- United
v3 (lumping missing&other category 
...Northeast; n (%)
59 (12.0%)
66 (13.5%)
-0.04
246 (17.8%)
232 (16.8%)
0.03
345 (20.3%)
339 (20.0%)
0.01
650 (18.2%)
637 (17.8%)
0.01
...South; n (%)
191 (39.0%)
187 (38.2%)
0.02
387 (28.0%)
397 (28.7%)
-0.02
609 (35.8%)
608 (35.8%)
0.00
1,187 (33.2%)
1,192 (33.4%)
0.00
...Midwest; n (%)
137 (28.0%)
136 (27.8%)
0.00
527 (38.2%)
526 (38.1%)
0.00
442 (26.0%)
468 (27.5%)
-0.03
1,106 (31.0%)
1,130 (31.7%)
-0.02
...West; n (%)
103 (21.0%)
101 (20.6%)
0.01
218 (15.8%)
223 (16.1%)
-0.01
303 (17.8%)
284 (16.7%)
0.03
624 (17.5%)
608 (17.0%)
0.01
...Unknown+missing; n (%)
N/A
N/A
#VALUE!
** (0.2%)
** (0.2%)
0.00
N/A
N/A
#VALUE!
** (0.2%)
** (0.2%)
0.00
CV Covariates
Ischemic heart disease; n (%)
90 (18.4%)
93 (19.0%)
-0.02
186 (13.5%)
158 (11.4%)
0.06
373 (22.0%)
375 (22.1%)
0.00
649 (18.2%)
626 (17.5%)
0.02
Acute MI; n (%)
23 (4.7%)
25 (5.1%)
-0.02
64 (4.6%)
59 (4.3%)
0.01
81 (4.8%)
84 (4.9%)
0.00
168 (4.7%)
168 (4.7%)
0.00
ACS/unstable angina; n (%)
18 (3.7%)
17 (3.5%)
0.01
44 (3.2%)
35 (2.5%)
0.04
74 (4.4%)
69 (4.1%)
0.01
136 (3.8%)
121 (3.4%)
0.02
Old MI; n (%)
18 (3.7%)
13 (2.7%)
0.06
16 (1.2%)
12 (0.9%)
0.03
89 (5.2%)
97 (5.7%)
-0.02
123 (3.4%)
122 (3.4%)
0.00
Stable angina; n (%)
** (1.4%)
** (1.0%)
0.04
19 (1.4%)
16 (1.2%)
0.02
42 (2.5%)
43 (2.5%)
0.00
#VALUE!
#VALUE!
#VALUE!
Coronary atherosclerosis and other 
forms of chronic ischemic heart disease; 
n (%)
62 (12.7%)
58 (11.8%)
0.03
104 (7.5%)
90 (6.5%)
0.04
266 (15.7%)
271 (16.0%)
-0.01
432 (12.1%)
419 (11.7%)
0.01
Other atherosclerosis with ICD10 v2 
Copy; n (%)
** (0.4%)
** (0.6%)
-0.03
** (0.4%)
** (0.3%)
0.02
12 (0.7%)
** (0.6%)
0.01
#VALUE!
#VALUE!
#VALUE!
Previous cardiac procedure (CABG or 
PTCA or Stent) v4; n (%)
** (0.4%)
0 (0.0%)
0.09
** (0.3%)
** (0.7%)
-0.06
** (0.6%)
** (0.4%)
0.03
#VALUE!
#VALUE!
#VALUE!
History of CABG or PTCA; n (%)
20 (4.1%)
14 (2.9%)
0.07
** (0.8%)
** (0.4%)
0.05
87 (5.1%)
96 (5.7%)
-0.03
#VALUE!
#VALUE!
#VALUE!
Any stroke; n (%)
** (1.6%)
** (1.0%)
0.05
13 (0.9%)
** (0.8%)
0.01
58 (3.4%)
58 (3.4%)
0.00
#VALUE!
#VALUE!
#VALUE!
Ischemic stroke (w and w/o mention of 
cerebral infarction); n (%)
** (1.6%)
** (1.0%)
0.05
13 (0.9%)
** (0.8%)
0.01
54 (3.2%)
56 (3.3%)
-0.01
#VALUE!
#VALUE!
#VALUE!
Hemorrhagic stroke; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.2%)
** (0.1%)
0.03
#VALUE!
#VALUE!
#VALUE!
TIA; n (%)
** (0.4%)
** (0.4%)
0.00
** (0.2%)
** (0.2%)
0.00
** (0.6%)
13 (0.8%)
-0.02
#VALUE!
#VALUE!
#VALUE!
Other cerebrovascular disease; n (%)
** (1.4%)
** (1.2%)
0.02
** (0.8%)
** (0.8%)
0.00
28 (1.6%)
30 (1.8%)
-0.02
#VALUE!
#VALUE!
#VALUE!
Cerebrovascular procedure; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
0 (0.0%)
0.04
#VALUE!
0 (0.0%)
#VALUE!
Heart failure (CHF); n (%)
52 (10.6%)
53 (10.8%)
-0.01
114 (8.3%)
115 (8.3%)
0.00
285 (16.8%)
304 (17.9%)
-0.03
451 (12.6%)
472 (13.2%)
-0.02
Peripheral Vascular Disease (PVD) or PVD 
Surgery v2; n (%)
16 (3.3%)
15 (3.1%)
0.01
31 (2.2%)
32 (2.3%)
-0.01
116 (6.8%)
111 (6.5%)
0.01
163 (4.6%)
158 (4.4%)
0.01
Atrial fibrillation; n (%)
36 (7.3%)
36 (7.3%)
0.00
90 (6.5%)
84 (6.1%)
0.02
178 (10.5%)
180 (10.6%)
0.00
304 (8.5%)
300 (8.4%)
0.00
Other cardiac dysrhythmia; n (%)
90 (18.4%)
90 (18.4%)
0.00
241 (17.5%)
234 (16.9%)
0.02
365 (21.5%)
379 (22.3%)
-0.02
696 (19.5%)
703 (19.7%)
-0.01
Cardiac conduction disorders; n (%)
28 (5.7%)
28 (5.7%)
0.00
87 (6.3%)
68 (4.9%)
0.06
126 (7.4%)
127 (7.5%)
0.00
241 (6.8%)
223 (6.2%)
0.02
Other CVD; n (%)
137 (28.0%)
132 (26.9%)
0.02
332 (24.0%)
359 (26.0%)
-0.05
420 (24.7%)
450 (26.5%)
-0.04
889 (24.9%)
941 (26.4%)
-0.03
Diabetes-related complications
Occurrence of Diabetic Neuropathy v2 
Copy; n (%)
18 (3.7%)
24 (4.9%)
-0.06
26 (1.9%)
25 (1.8%)
0.01
100 (5.9%)
99 (5.8%)
0.00
144 (4.0%)
148 (4.1%)
-0.01
Occurrence of diabetic nephropathy V3 
with ICD10 Copy; n (%)
13 (2.7%)
** (1.2%)
0.11
18 (1.3%)
14 (1.0%)
0.03
47 (2.8%)
31 (1.8%)
0.07
78 (2.2%)
#VALUE!
#VALUE!
Hypoglycemia v2; n (%)
** (0.6%)
** (0.2%)
0.06
** (0.2%)
** (0.1%)
0.03
51 (3.0%)
44 (2.6%)
0.02
#VALUE!
#VALUE!
#VALUE!
Hyperglycemia; n (%)
53 (10.8%)
41 (8.4%)
0.08
76 (5.5%)
80 (5.8%)
-0.01
151 (8.9%)
158 (9.3%)
-0.01
280 (7.8%)
279 (7.8%)
0.00
Diabetic ketoacidosis; n (%)
** (0.6%)
** (0.4%)
0.03
** (0.1%)
** (0.7%)
-0.10
** (0.4%)
** (0.4%)
0.00
#VALUE!
#VALUE!
#VALUE!
Hypertension: 1 inpatient or 2 
outpatient claims within 365 days; n (%)
207 (42.2%)
210 (42.9%)
-0.01
553 (40.0%)
564 (40.8%)
-0.02
775 (45.6%)
782 (46.0%)
-0.01
1,535 (43.0%)
1,556 (43.6%)
-0.01
Hyperlipidemia v2; n (%)
172 (35.1%)
171 (34.9%)
0.00
419 (30.3%)
405 (29.3%)
0.02
709 (41.7%)
710 (41.8%)
0.00
1,300 (36.4%)
1,286 (36.0%)
0.01
Edema; n (%)
92 (18.8%)
74 (15.1%)
0.10
194 (14.0%)
188 (13.6%)
0.01
279 (16.4%)
281 (16.5%)
0.00
565 (15.8%)
543 (15.2%)
0.02
Renal Dysfunction (non-diabetic) v2; n 
(%)
76 (15.5%)
80 (16.3%)
-0.02
188 (13.6%)
179 (13.0%)
0.02
297 (17.5%)
334 (19.7%)
-0.06
561 (15.7%)
593 (16.6%)
-0.02
Occurrence of acute renal disease v2; n 
(%)
36 (7.3%)
43 (8.8%)
-0.06
97 (7.0%)
98 (7.1%)
0.00
166 (9.8%)
183 (10.8%)
-0.03
299 (8.4%)
324 (9.1%)
-0.02
Occurrence of chronic renal 
insufficiency; n (%)
27 (5.5%)
25 (5.1%)
0.02
44 (3.2%)
32 (2.3%)
0.06
109 (6.4%)
128 (7.5%)
-0.04
180 (5.0%)
185 (5.2%)
-0.01
 PS-matched
MarketScan
Medicare
POOLED
Optum
Appendix B 

Chronic kidney disease v2; n (%)
24 (4.9%)
23 (4.7%)
0.01
41 (3.0%)
29 (2.1%)
0.06
105 (6.2%)
124 (7.3%)
-0.04
170 (4.8%)
176 (4.9%)
0.00
CKD Stage 3-4; n (%)
16 (3.3%)
15 (3.1%)
0.01
34 (2.5%)
23 (1.7%)
0.06
79 (4.6%)
92 (5.4%)
-0.04
129 (3.6%)
130 (3.6%)
0.00
Occurrence of hypertensive 
nephropathy; n (%)
15 (3.1%)
17 (3.5%)
-0.02
30 (2.2%)
21 (1.5%)
0.05
63 (3.7%)
73 (4.3%)
-0.03
108 (3.0%)
111 (3.1%)
-0.01
Occurrence of miscellaneous renal 
insufficiency v2; n (%)
31 (6.3%)
34 (6.9%)
-0.02
88 (6.4%)
77 (5.6%)
0.03
109 (6.4%)
117 (6.9%)
-0.02
228 (6.4%)
228 (6.4%)
0.00
Other Covariates
Liver disease; n (%)
** (0.4%)
0 (0.0%)
0.09
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.4%)
** (0.3%)
0.02
#VALUE!
#VALUE!
#VALUE!
Osteoarthritis; n (%)
104 (21.2%)
112 (22.9%)
-0.04
226 (16.4%)
233 (16.9%)
-0.01
436 (25.7%)
414 (24.4%)
0.03
766 (21.5%)
759 (21.3%)
0.00
Other arthritis, arthropathies and 
musculoskeletal pain; n (%)
282 (57.6%)
277 (56.5%)
0.02
771 (55.8%)
760 (55.0%)
0.02
997 (58.7%)
996 (58.6%)
0.00
2050 (57.4%)
2033 (56.9%)
0.01
Dorsopathies; n (%)
154 (31.4%)
165 (33.7%)
-0.05
368 (26.6%)
358 (25.9%)
0.02
589 (34.7%)
579 (34.1%)
0.01
1111 (31.1%)
1102 (30.9%)
0.00
Fractures; n (%)
26 (5.3%)
28 (5.7%)
-0.02
40 (2.9%)
47 (3.4%)
-0.03
123 (7.2%)
135 (7.9%)
-0.03
189 (5.3%)
210 (5.9%)
-0.03
Falls v2; n (%)
33 (6.7%)
38 (7.8%)
-0.04
29 (2.1%)
26 (1.9%)
0.01
88 (5.2%)
89 (5.2%)
0.00
150 (4.2%)
153 (4.3%)
0.00
Osteoporosis; n (%)
19 (3.9%)
23 (4.7%)
-0.04
31 (2.2%)
28 (2.0%)
0.01
147 (8.7%)
146 (8.6%)
0.00
197 (5.5%)
197 (5.5%)
0.00
Depression; n (%)
100 (20.4%)
96 (19.6%)
0.02
188 (13.6%)
196 (14.2%)
-0.02
479 (28.2%)
471 (27.7%)
0.01
767 (21.5%)
763 (21.4%)
0.00
Anxiety; n (%)
113 (23.1%)
116 (23.7%)
-0.01
236 (17.1%)
250 (18.1%)
-0.03
483 (28.4%)
481 (28.3%)
0.00
832 (23.3%)
847 (23.7%)
-0.01
Sleep_Disorder; n (%)
21 (4.3%)
25 (5.1%)
-0.04
64 (4.6%)
66 (4.8%)
-0.01
83 (4.9%)
80 (4.7%)
0.01
168 (4.7%)
171 (4.8%)
0.00
Dementia; n (%)
26 (5.3%)
29 (5.9%)
-0.03
27 (2.0%)
33 (2.4%)
-0.03
207 (12.2%)
218 (12.8%)
-0.02
260 (7.3%)
280 (7.8%)
-0.02
Delirium; n (%)
16 (3.3%)
16 (3.3%)
0.00
21 (1.5%)
23 (1.7%)
-0.02
137 (8.1%)
136 (8.0%)
0.00
174 (4.9%)
175 (4.9%)
0.00
Psychosis; n (%)
** (1.8%)
12 (2.4%)
-0.04
15 (1.1%)
13 (0.9%)
0.02
154 (9.1%)
160 (9.4%)
-0.01
#VALUE!
185 (5.2%)
#VALUE!
Obesity; n (%)
188 (38.4%)
193 (39.4%)
-0.02
502 (36.4%)
507 (36.7%)
-0.01
472 (27.8%)
483 (28.4%)
-0.01
1162 (32.5%)
1183 (33.1%)
-0.01
Overweight; n (%)
23 (4.7%)
27 (5.5%)
-0.04
49 (3.5%)
57 (4.1%)
-0.03
70 (4.1%)
63 (3.7%)
0.02
142 (4.0%)
147 (4.1%)
-0.01
Smoking; n (%)
192 (39.2%)
196 (40.0%)
-0.02
255 (18.5%)
250 (18.1%)
0.01
829 (48.8%)
826 (48.6%)
0.00
1276 (35.7%)
1272 (35.6%)
0.00
Alcohol abuse or dependence; n (%)
** (2.0%)
** (1.6%)
0.03
18 (1.3%)
16 (1.2%)
0.01
39 (2.3%)
38 (2.2%)
0.01
#VALUE!
#VALUE!
#VALUE!
Drug abuse or dependence; n (%)
26 (5.3%)
29 (5.9%)
-0.03
29 (2.1%)
35 (2.5%)
-0.03
131 (7.7%)
118 (6.9%)
0.03
186 (5.2%)
182 (5.1%)
0.00
COPD; n (%)
92 (18.8%)
97 (19.8%)
-0.03
122 (8.8%)
129 (9.3%)
-0.02
482 (28.4%)
481 (28.3%)
0.00
696 (19.5%)
707 (19.8%)
-0.01
Asthma; n (%)
68 (13.9%)
63 (12.9%)
0.03
160 (11.6%)
163 (11.8%)
-0.01
251 (14.8%)
263 (15.5%)
-0.02
479 (13.4%)
489 (13.7%)
-0.01
Obstructive sleep apnea; n (%)
90 (18.4%)
95 (19.4%)
-0.03
215 (15.6%)
212 (15.4%)
0.01
255 (15.0%)
258 (15.2%)
-0.01
560 (15.7%)
565 (15.8%)
0.00
Pneumonia; n (%)
89 (18.2%)
87 (17.8%)
0.01
217 (15.7%)
229 (16.6%)
-0.02
417 (24.5%)
403 (23.7%)
0.02
723 (20.3%)
719 (20.1%)
0.00
Other Medications
Use of ACE inhibitors; n (%)
75 (15.3%)
70 (14.3%)
0.03
220 (15.9%)
222 (16.1%)
-0.01
266 (15.7%)
261 (15.4%)
0.01
561 (15.7%)
553 (15.5%)
0.01
Use of ARBs; n (%)
34 (6.9%)
42 (8.6%)
-0.06
124 (9.0%)
132 (9.6%)
-0.02
84 (4.9%)
79 (4.6%)
0.01
242 (6.8%)
253 (7.1%)
-0.01
Use of Loop Diuretics - United; n (%)
47 (9.6%)
49 (10.0%)
-0.01
94 (6.8%)
94 (6.8%)
0.00
236 (13.9%)
243 (14.3%)
-0.01
377 (10.6%)
386 (10.8%)
-0.01
Use of other diuretics- United; n (%)
18 (3.7%)
13 (2.7%)
0.06
30 (2.2%)
22 (1.6%)
0.04
47 (2.8%)
53 (3.1%)
-0.02
95 (2.7%)
88 (2.5%)
0.01
Use of nitrates-United; n (%)
** (1.6%)
** (1.2%)
0.03
20 (1.4%)
19 (1.4%)
0.00
65 (3.8%)
63 (3.7%)
0.01
#VALUE!
#VALUE!
#VALUE!
Use of other hypertension drugs; n (%)
14 (2.9%)
16 (3.3%)
-0.02
37 (2.7%)
41 (3.0%)
-0.02
85 (5.0%)
92 (5.4%)
-0.02
136 (3.8%)
149 (4.2%)
-0.02
Use of Anti-arrhythmics; n (%)
** (1.4%)
** (1.8%)
-0.03
18 (1.3%)
21 (1.5%)
-0.02
24 (1.4%)
31 (1.8%)
-0.03
#VALUE!
#VALUE!
#VALUE!
Use of COPD/asthma meds- United; n (%)
91 (18.6%)
87 (17.8%)
0.02
203 (14.7%)
255 (18.5%)
-0.10
398 (23.4%)
389 (22.9%)
0.01
692 (19.4%)
731 (20.5%)
-0.03
Use of statins; n (%)
111 (22.7%)
111 (22.7%)
0.00
261 (18.9%)
259 (18.8%)
0.00
468 (27.5%)
468 (27.5%)
0.00
840 (23.5%)
838 (23.5%)
0.00
Use of other lipid-lowering drugs; n (%)
20 (4.1%)
18 (3.7%)
0.02
52 (3.8%)
48 (3.5%)
0.02
77 (4.5%)
78 (4.6%)
0.00
149 (4.2%)
144 (4.0%)
0.01
Use of antiplatelet agents; n (%)
** (1.6%)
** (2.0%)
-0.03
26 (1.9%)
31 (2.2%)
-0.02
95 (5.6%)
81 (4.8%)
0.04
#VALUE!
#VALUE!
#VALUE!
Use of heparin and other low-molecular 
weight heparins; n (%)
95 (19.4%)
101 (20.6%)
-0.03
1 (0.1%)
0 (0.0%)
0.04
156 (9.2%)
153 (9.0%)
0.01
252 (7.1%)
254 (7.1%)
0.00
Use of NSAIDs; n (%)
47 (9.6%)
55 (11.2%)
-0.05
205 (14.8%)
209 (15.1%)
-0.01
203 (11.9%)
193 (11.4%)
0.02
455 (12.7%)
457 (12.8%)
0.00
Use of opioids- United; n (%)
199 (40.6%)
193 (39.4%)
0.02
631 (45.7%)
622 (45.0%)
0.01
740 (43.6%)
718 (42.3%)
0.03
1570 (44.0%)
1533 (42.9%)
0.02
Use of antidepressants; n (%)
137 (28.0%)
135 (27.6%)
0.01
322 (23.3%)
338 (24.5%)
-0.03
683 (40.2%)
671 (39.5%)
0.01
1142 (32.0%)
1144 (32.0%)
0.00
Use of antipsychotics; n (%)
27 (5.5%)
32 (6.5%)
-0.04
58 (4.2%)
57 (4.1%)
0.01
285 (16.8%)
287 (16.9%)
0.00
370 (10.4%)
376 (10.5%)
0.00
Labs
1,871 
1,871 
Lab values- HbA1c (%) v3; n (%)
52 (10.6%)
49 (10.0%)
0.02
** (0.2%)
21 (1.5%)
-0.14
N/A
N/A
#VALUE!
#VALUE!
070 (3.7%)
#VALUE!
Lab values- HbA1c (%) (within 3 months) 
v3; n (%)
28 (5.7%)
29 (5.9%)
-0.01
** (0.1%)
12 (0.9%)
-0.11
N/A
N/A
#VALUE!
#VALUE!
041 (2.2%)
#VALUE!
Lab values- HbA1c (%) (within 6 months) 
v3; n (%)
52 (10.6%)
49 (10.0%)
0.02
** (0.2%)
21 (1.5%)
-0.14
N/A
N/A
#VALUE!
#VALUE!
070 (3.7%)
#VALUE!
Lab values- BNP; n (%)
** (1.0%)
** (2.0%)
-0.08
0 (0.0%)
** (0.2%)
-0.06
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- BNP (within 3 months); n (%)
** (1.0%)
** (2.0%)
-0.08
0 (0.0%)
** (0.2%)
-0.06
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- BNP (within 6 months); n (%)
** (1.0%)
** (2.0%)
-0.08
0 (0.0%)
** (0.2%)
-0.06
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- BUN (mg/dl); n (%)
107 (21.8%)
107 (21.8%)
0.00
** (0.8%)
21 (1.5%)
-0.07
N/A
N/A
#VALUE!
#VALUE!
128 (6.8%)
#VALUE!
Lab values- BUN (mg/dl) (within 3 
months); n (%)
72 (14.7%)
80 (16.3%)
-0.04
** (0.4%)
12 (0.9%)
-0.06
N/A
N/A
#VALUE!
#VALUE!
092 (4.9%)
#VALUE!
Lab values- BUN (mg/dl) (within 6 
months); n (%)
107 (21.8%)
107 (21.8%)
0.00
** (0.8%)
21 (1.5%)
-0.07
N/A
N/A
#VALUE!
#VALUE!
128 (6.8%)
#VALUE!
Lab values- Creatinine (mg/dl) v2; n (%)
109 (22.2%)
115 (23.5%)
-0.03
** (0.8%)
23 (1.7%)
-0.08
N/A
N/A
#VALUE!
#VALUE!
138 (7.4%)
#VALUE!
Lab values- Creatinine (mg/dl) (within 3 
months) v2; n (%)
73 (14.9%)
87 (17.8%)
-0.08
** (0.4%)
13 (0.9%)
-0.06
N/A
N/A
#VALUE!
#VALUE!
100 (5.3%)
#VALUE!
Lab values- Creatinine (mg/dl) (within 6 
months) v2; n (%)
109 (22.2%)
115 (23.5%)
-0.03
** (0.8%)
23 (1.7%)
-0.08
N/A
N/A
#VALUE!
#VALUE!
138 (7.4%)
#VALUE!
Lab values- HDL level (mg/dl); n (%)
58 (11.8%)
66 (13.5%)
-0.05
** (0.4%)
20 (1.4%)
-0.11
N/A
N/A
#VALUE!
#VALUE!
086 (4.6%)
#VALUE!
Lab values- HDL level (mg/dl) (within 3 
months); n (%)
34 (6.9%)
42 (8.6%)
-0.06
** (0.1%)
** (0.8%)
-0.10
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- HDL level (mg/dl) (within 6 
months); n (%)
58 (11.8%)
66 (13.5%)
-0.05
** (0.4%)
20 (1.4%)
-0.11
N/A
N/A
#VALUE!
#VALUE!
086 (4.6%)
#VALUE!
Lab values- LDL level (mg/dl) v2; n (%)
59 (12.0%)
69 (14.1%)
-0.06
** (0.4%)
19 (1.4%)
-0.11
N/A
N/A
#VALUE!
#VALUE!
088 (4.7%)
#VALUE!
Appendix B 

Lab values- LDL level (mg/dl) (within 3 
months) v2; n (%)
34 (6.9%)
43 (8.8%)
-0.07
** (0.2%)
** (0.8%)
-0.09
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- LDL level (mg/dl) (within 6 
months) v2; n (%)
59 (12.0%)
69 (14.1%)
-0.06
** (0.4%)
19 (1.4%)
-0.11
N/A
N/A
#VALUE!
#VALUE!
088 (4.7%)
#VALUE!
Lab values- NT-proBNP; n (%)
** (0.8%)
0 (0.0%)
0.13
0 (0.0%)
0 (0.0%)
#DIV/0!
N/A
N/A
#VALUE!
#VALUE!
0 (0.0%)
#VALUE!
Lab values- NT-proBNP (within 3 
months); n (%)
** (0.8%)
0 (0.0%)
0.13
0 (0.0%)
0 (0.0%)
#DIV/0!
N/A
N/A
#VALUE!
#VALUE!
0 (0.0%)
-
Lab values- NT-proBNP (within 6 
months); n (%)
** (0.8%)
0 (0.0%)
0.13
0 (0.0%)
0 (0.0%)
#DIV/0!
N/A
N/A
#VALUE!
#VALUE!
0 (0.0%)
-
Lab values- Total cholesterol (mg/dl) v2; 
n (%)
60 (12.2%)
69 (14.1%)
-0.06
** (0.3%)
20 (1.4%)
-0.12
N/A
N/A
#VALUE!
#VALUE!
089 (4.8%)
#VALUE!
Lab values- Total cholesterol (mg/dl) 
(within 3 months) v2; n (%)
35 (7.1%)
43 (8.8%)
-0.06
** (0.1%)
** (0.8%)
-0.10
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- Total cholesterol (mg/dl) 
(within 6 months) v2; n (%)
60 (12.2%)
69 (14.1%)
-0.06
** (0.3%)
20 (1.4%)
-0.12
N/A
N/A
#VALUE!
#VALUE!
089 (4.8%)
#VALUE!
Lab values- Triglyceride level (mg/dl); n 
(%)
60 (12.2%)
68 (13.9%)
-0.05
** (0.4%)
19 (1.4%)
-0.11
N/A
N/A
#VALUE!
#VALUE!
087 (4.6%)
#VALUE!
Lab values- Triglyceride level (mg/dl) 
(within 3 months); n (%)
35 (7.1%)
43 (8.8%)
-0.06
** (0.1%)
** (0.8%)
-0.10
N/A
N/A
#VALUE!
#VALUE!
#VALUE!
#VALUE!
Lab values- Triglyceride level (mg/dl) 
(within 6 months); n (%)
60 (12.2%)
68 (13.9%)
-0.05
** (0.4%)
19 (1.4%)
-0.11
N/A
N/A
#VALUE!
#VALUE!
087 (4.6%)
#VALUE!
Lab result number- HbA1c (%) mean 
(only 2 to 20 included) v4
52
 
49
 
3 
21
 
N/A
N/A
55 
70 
...mean (sd)
6.43 (1.98)
6.63 (1.68)
-0.11
7.47 (1.98)
6.61 (1.26)
0.52
N/A
N/A
#VALUE!
6.49 (2.00)
6.62 (1.58)
-0.07
...Missing; n (%)
438 (89.4%)
441 (90.0%)
-0.02
1,378 (99.8%)
1,360 (98.5%)
0.14
N/A
N/A
#VALUE!
1,816 (97.1%)
1,801 (96.3%)
0.04
Lab result number- BNP mean v2
5 
10
 
- 
3 
N/A
N/A
5 
13 
...mean (sd)
82.32 (68.33)
593.05 (1,341.63)
-0.54
- (-)
1,474.33 (2,513.81)
#VALUE!
N/A
N/A
#VALUE!
#VALUE!
796.42 (1698.18)
#VALUE!
...Missing; n (%)
485 (99.0%)
480 (98.0%)
0.08
1,381 (100.0%)
1,378 (99.8%)
0.06
N/A
N/A
#VALUE!
1,866 (99.7%)
1,858 (99.3%)
0.06
Lab result number- BUN (mg/dl) mean v2
107 
107 
11 
21 
N/A
N/A
118 
128 
...mean (sd)
14.59 (4.94)
14.77 (5.11)
-0.04
18,197.88 (44,223.54)
14.28 (4.67)
0.58
N/A
N/A
#VALUE!
1709.64 (13040.81)
14.69 (5.06)
0.18
...Missing; n (%)
383 (78.2%)
383 (78.2%)
0.00
1,370 (99.2%)
1,360 (98.5%)
0.07
N/A
N/A
#VALUE!
1,753 (93.7%)
1,743 (93.2%)
0.02
Lab result number- Creatinine (mg/dl) 
mean (only 0.1 to 15 included) v3
109 
115 
9 
23 
N/A
N/A
118 
138 
...mean (sd)
0.89 (0.22)
0.90 (0.23)
-0.04
1.02 (0.21)
0.94 (0.18)
0.41
N/A
N/A
#VALUE!
0.90 (0.22)
0.91 (0.22)
-0.05
...Missing; n (%)
381 (77.8%)
375 (76.5%)
0.03
1,372 (99.3%)
1,358 (98.3%)
0.09
N/A
N/A
#VALUE!
1,753 (93.7%)
1,733 (92.6%)
0.04
Lab result number- HDL level (mg/dl) 
mean (only =<5000 included) v2
58 
66 
4 
20 
N/A
N/A
62 
86 
...mean (sd)
53.28 (16.01)
51.19 (15.56)
0.13
43.75 (16.07)
45.90 (14.63)
-0.14
N/A
N/A
#VALUE!
52.67 (16.15)
49.96 (15.45)
0.17
...Missing; n (%)
432 (88.2%)
424 (86.5%)
0.05
1,377 (99.7%)
1,361 (98.6%)
0.12
N/A
N/A
#VALUE!
1,809 (96.7%)
1,785 (95.4%)
0.07
Lab result number- LDL level (mg/dl) 
mean (only =<5000 included) v2
58 
68 
4 
17 
N/A
N/A
62 
85 
...mean (sd)
113.22 (39.81)
110.23 (37.87)
0.08
80.50 (59.31)
88.47 (23.32)
-0.18
N/A
N/A
#VALUE!
111.11 (41.35)
105.88 (35.75)
0.14
...Missing; n (%)
432 (88.2%)
422 (86.1%)
0.06
1,377 (99.7%)
1,364 (98.8%)
0.10
N/A
N/A
#VALUE!
1,809 (96.7%)
1,786 (95.5%)
0.06
Lab result number- Total cholesterol 
(mg/dl) mean (only =<5000 included) v2
60 
69 
3 
20 
N/A
N/A
63 
89 
...mean (sd)
193.95 (42.54)
190.48 (38.93)
0.09
186.67 (41.79)
161.78 (32.05)
0.67
N/A
N/A
#VALUE!
193.60 (42.87)
184.03 (37.75)
0.24
...Missing; n (%)
430 (87.8%)
421 (85.9%)
0.06
1,378 (99.8%)
1,361 (98.6%)
0.14
N/A
N/A
#VALUE!
1,808 (96.6%)
1,782 (95.2%)
0.07
Lab result number- Triglyceride level 
(mg/dl) mean (only =<5000 included) v2
60 
68 
4 
19 
N/A
N/A
64 
87 
...mean (sd)
139.10 (84.71)
141.70 (80.32)
-0.03
248.00 (206.07)
124.68 (70.13)
0.80
N/A
N/A
#VALUE!
145.91 (95.02)
137.98 (78.74)
0.09
...Missing; n (%)
430 (87.8%)
422 (86.1%)
0.05
1,377 (99.7%)
1,362 (98.6%)
0.12
N/A
N/A
#VALUE!
1,807 (96.6%)
1,784 (95.4%)
0.06
Lab result number- Hemoglobin mean 
(only >0 included)
83 
97 
6 
17 
N/A
N/A
89 
114 
...mean (sd)
13.73 (1.94)
13.73 (1.83)
0.00
40,008.30 (62,283.25)
14.48 (1.45)
0.91
N/A
N/A
#VALUE!
2709.99 (15017.83)
13.84 (1.79)
0.25
...Missing; n (%)
407 (83.1%)
393 (80.2%)
0.07
1,375 (99.6%)
1,364 (98.8%)
0.09
N/A
N/A
#VALUE!
1,782 (95.2%)
1,757 (93.9%)
0.06
Lab result number- Serum sodium mean 
(only > 90 and < 190 included)
103 
102 
9 
22 
N/A
N/A
112 
124 
...mean (sd)
140.36 (2.80)
140.11 (2.59)
0.09
137.64 (4.57)
140.09 (1.89)
-0.70
N/A
N/A
#VALUE!
140.14 (2.98)
140.11 (2.49)
0.01
...Missing; n (%)
387 (79.0%)
388 (79.2%)
0.00
1,372 (99.3%)
1,359 (98.4%)
0.08
N/A
N/A
#VALUE!
1,759 (94.0%)
1,747 (93.4%)
0.02
Lab result number- Albumin mean (only 
>0 and <=10 included)
95 
100 
8 
16 
N/A
N/A
103 
116 
...mean (sd)
4.08 (0.41)
4.08 (0.40)
0.00
4.00 (0.32)
4.16 (0.48)
-0.39
N/A
N/A
#VALUE!
4.07 (0.41)
4.09 (0.41)
-0.05
...Missing; n (%)
395 (80.6%)
390 (79.6%)
0.03
1,373 (99.4%)
1,365 (98.8%)
0.06
N/A
N/A
#VALUE!
1,768 (94.5%)
1,755 (93.8%)
0.03
Lab result number- Glucose (fasting or 
random) mean (only 10-1000 included)
103 
103 
9 
23 
N/A
N/A
112 
126 
...mean (sd)
112.05 (46.57)
108.13 (37.41)
0.09
166.42 (108.75)
131.56 (58.94)
0.40
N/A
N/A
#VALUE!
116.42 (53.83)
112.41 (42.21)
0.08
...Missing; n (%)
387 (79.0%)
387 (79.0%)
0.00
1,372 (99.3%)
1,358 (98.3%)
0.09
N/A
N/A
#VALUE!
1,759 (94.0%)
1,745 (93.3%)
0.03
Lab result number- Potassium mean 
(only 1-7 included)
107 
112 
9 
20 
N/A
N/A
116 
132 
...mean (sd)
4.34 (0.42)
4.34 (0.40)
0.00
4.37 (0.55)
4.37 (0.40)
0.00
N/A
N/A
#VALUE!
4.34 (0.43)
4.34 (0.40)
0.00
...Missing; n (%)
383 (78.2%)
378 (77.1%)
0.03
1,372 (99.3%)
1,361 (98.6%)
0.07
N/A
N/A
#VALUE!
1,755 (93.8%)
1,739 (92.9%)
0.04
Comorbidity Scores
CCI (180 days)- ICD9 and ICD10 v2
...mean (sd)
3.51 (2.21)
3.71 (2.52)
-0.08
2.89 (2.11)
2.83 (2.17)
0.03
3.97 (2.69)
4.05 (2.67)
-0.03
3.49 (2.42)
3.53 (2.47)
-0.02
Appendix B 

Non-Frailty; n (%)
206 (42.0%)
210 (42.9%)
-0.02
581 (42.1%)
583 (42.2%)
0.00
57 (3.4%)
47 (2.8%)
0.03
844 (23.6%)
840 (23.5%)
0.00
Frailty Score (mean): Empirical Version 
365 days, v2
...mean (sd)
0.18 (0.06)
0.18 (0.06)
0.00
0.15 (0.05)
0.15 (0.05)
0.00
0.10 (0.07)
0.10 (0.08)
0.00
0.13 (0.06)
0.13 (0.07)
0.00
Healthcare Utilization
Any hospitalization; n (%)
438 (89.4%)
453 (92.4%)
-0.10
1,379 (99.9%)
1,380 (99.9%)
0.00
1,564 (92.1%)
1,555 (91.5%)
0.02
3,381 (94.7%)
3,388 (94.9%)
-0.01
Any hospitalization within prior 30 
days; n (%)
374 (76.3%)
364 (74.3%)
0.05
1,287 (93.2%)
1,302 (94.3%)
-0.05
1,204 (70.9%)
1,229 (72.3%)
-0.03
2865 (80.3%)
2895 (81.1%)
-0.02
Any hospitalization during prior 31-180 
days; n (%)
101 (20.6%)
121 (24.7%)
-0.10
185 (13.4%)
166 (12.0%)
0.04
565 (33.3%)
546 (32.1%)
0.03
851 (23.8%)
833 (23.3%)
0.01
Internal medicine/family medicine 
visits; n (%)
427 (87.1%)
427 (87.1%)
0.00
1,079 (78.1%)
1,090 (78.9%)
-0.02
1,606 (94.5%)
1,626 (95.7%)
-0.06
3112 (87.2%)
3143 (88.0%)
-0.02
Internal medicine/family medicine visits 
(30 days prior) v2; n (%)
361 (73.7%)
360 (73.5%)
0.00
753 (54.5%)
821 (59.4%)
-0.10
1,399 (82.3%)
1,402 (82.5%)
-0.01
2513 (70.4%)
2583 (72.4%)
-0.04
Internal medicine/family medicine visits 
(31 to 180 days prior) v2; n (%)
294 (60.0%)
294 (60.0%)
0.00
855 (61.9%)
817 (59.2%)
0.06
1,184 (69.7%)
1,140 (67.1%)
0.06
2333 (65.4%)
2251 (63.1%)
0.05
Cardiologist visit; n (%)
352 (71.8%)
365 (74.5%)
-0.06
393 (28.5%)
375 (27.2%)
0.03
1,203 (70.8%)
1,213 (71.4%)
-0.01
1948 (54.6%)
1953 (54.7%)
0.00
Number of Cardiologist visits (30 days 
prior); n (%)
297 (60.6%)
308 (62.9%)
-0.05
271 (19.6%)
270 (19.6%)
0.00
880 (51.8%)
902 (53.1%)
-0.03
1448 (40.6%)
1480 (41.5%)
-0.02
Number of Cardiologist visits (31 to 180 
days prior); n (%)
111 (22.7%)
123 (25.1%)
-0.06
173 (12.5%)
165 (11.9%)
0.02
558 (32.8%)
563 (33.1%)
-0.01
842 (23.6%)
851 (23.8%)
0.00
Electrocardiogram v2; n (%)
401 (81.8%)
415 (84.7%)
-0.08
694 (50.3%)
691 (50.0%)
0.01
1,449 (85.3%)
1,442 (84.9%)
0.01
2544 (71.3%)
2548 (71.4%)
0.00
Use of glucose test strips; n (%)
** (1.2%)
** (1.4%)
-0.02
19 (1.4%)
** (0.8%)
0.06
31 (1.8%)
29 (1.7%)
0.01
#VALUE!
#VALUE!
#VALUE!
Dialysis; n (%)
0 (0.0%)
** (0.2%)
-0.06
0 (0.0%)
** (0.1%)
-0.04
** (0.1%)
** (0.1%)
0.00
#VALUE!
#VALUE!
#VALUE!
number of different/distinct medication 
prescriptions
...mean (sd)
7.88 (5.51)
8.00 (5.83)
-0.02
7.89 (4.81)
8.01 (5.76)
-0.02
9.33 (6.22)
9.31 (6.22)
0.00
8.57 (5.62)
8.63 (5.99)
-0.01
Number of Hospitalizations
...mean (sd)
1.11 (0.72)
1.08 (0.56)
0.05
1.17 (0.48)
1.16 (0.49)
0.02
1.30 (0.93)
1.29 (0.93)
0.01
1.22 (0.76)
1.21 (0.74)
0.01
Number of hospital days
...mean (sd)
5.44 (4.46)
5.11 (7.06)
0.06
5.43 (4.09)
5.28 (6.21)
0.03
5.85 (5.04)
5.73 (7.43)
0.02
5.63 (4.61)
5.47 (6.93)
0.03
Number of Emergency Department (ED) 
visits v3
...mean (sd)
1.79 (2.37)
1.82 (2.21)
-0.01
3.20 (5.17)
3.17 (4.44)
0.01
2.70 (7.14)
2.73 (4.23)
-0.01
2.77 (5.95)
2.78 (4.10)
0.00
Number of Office visits
...mean (sd)
5.01 (4.71)
5.03 (4.44)
0.00
4.72 (4.41)
4.77 (5.34)
-0.01
10.37 (13.98)
10.07 (11.65)
0.02
7.45 (10.18)
7.33 (8.85)
0.01
Number of internal medicine/family 
medicine visits
...mean (sd)
10.16 (13.90)
9.39 (12.98)
0.06
5.30 (7.34)
5.51 (8.85)
-0.03
12.46 (13.83)
11.04 (12.11)
0.11
9.37 (11.76)
8.67 (11.10)
0.06
Number of Cardiologist visits
...mean (sd)
2.58 (3.80)
2.62 (3.94)
-0.01
0.71 (1.95)
0.70 (1.90)
0.01
2.81 (4.52)
2.89 (4.25)
-0.02
1.97 (3.63)
2.01 (3.48)
-0.01
Number electrocardiograms received v2
...mean (sd)
1.98 (2.00)
2.10 (2.02)
-0.06
0.90 (1.31)
0.92 (1.37)
-0.01
2.31 (2.51)
2.35 (2.54)
-0.02
1.72 (2.05)
1.76 (2.09)
-0.02
Number of HbA1c tests ordered
...mean (sd)
0.28 (0.63)
0.29 (0.64)
-0.02
0.22 (0.51)
0.22 (0.55)
0.00
0.29 (0.62)
0.29 (0.60)
0.00
0.26 (0.58)
0.26 (0.59)
0.00
Number of glucose tests ordered
...mean (sd)
0.14 (0.62)
0.17 (0.73)
-0.04
0.13 (1.17)
0.13 (0.60)
0.00
0.15 (0.60)
0.17 (0.60)
-0.03
0.14 (0.87)
0.15 (0.62)
-0.01
Number of lipid tests ordered
...mean (sd)
0.37 (0.62)
0.39 (0.74)
-0.03
0.38 (0.72)
0.36 (0.66)
0.03
0.36 (0.65)
0.37 (0.64)
-0.02
0.37 (0.67)
0.37 (0.66)
0.00
Total N distinct ICD9/ICD10 diagnoses at 
the 3rd digit level Copy
...mean (sd)
12.13 (12.97)
12.28 (12.70)
-0.01
10.37 (10.13)
10.29 (10.87)
0.01
17.46 (15.46)
17.28 (15.89)
0.01
13.99 (13.29)
13.89 (13.71)
0.01
For PS
Hemorrhagic stroke+Other 
cerebrovascular 
disease+Cerebrovascular procedure (for 
PS); n (%)
** (1.4%)
** (1.2%)
0.02
11 (0.8%)
11 (0.8%)
0.00
31 (1.8%)
31 (1.8%)
0.00
#VALUE!
#VALUE!
#VALUE!
Major trauma potentially causing prolong19 (3.9%)
16 (3.3%)
#DIV/0!
31 (2.2%)
33 (2.4%)
#DIV/0!
92 (5.4%)
92 (5.4%)
#DIV/0!
31 (2.2%)
33 (2.4%)
-0.01
Occurrence of creatinine tests ordered 
(for PS); n (%)
30 (6.1%)
30 (6.1%)
0.00
80 (5.8%)
72 (5.2%)
0.03
129 (7.6%)
151 (8.9%)
-0.05
239 (6.7%)
253 (7.1%)
-0.02
Occurrence of BUN tests ordered (for 
PS); n (%)
13 (2.7%)
15 (3.1%)
-0.02
36 (2.6%)
42 (3.0%)
-0.02
63 (3.7%)
81 (4.8%)
-0.05
112 (3.1%)
138 (3.9%)
-0.04
Occurrence of chronic renal 
insufficiency w/o CKD (for PS) v2; n (%)
** (1.0%)
** (0.6%)
0.04
** (0.5%)
** (0.5%)
0.00
18 (1.1%)
26 (1.5%)
-0.04
#VALUE!
#VALUE!
#VALUE!
Chronic kidney disease Stage 1-2 (for PS); 
n (%)
** (1.4%)
** (1.6%)
-0.02
** (0.7%)
** (0.4%)
0.04
28 (1.6%)
27 (1.6%)
0.00
#VALUE!
#VALUE!
#VALUE!
Chronic kidney disease Stage 3-6 (for PS); 
n (%)
16 (3.3%)
15 (3.1%)
0.01
34 (2.5%)
23 (1.7%)
0.06
79 (4.6%)
92 (5.4%)
-0.04
129 (3.6%)
130 (3.6%)
0.00
Acute kidney injury; n (%)
38 (7.8%)
43 (8.8%)
#DIV/0!
99 (7.2%)
98 (7.1%)
#DIV/0!
168 (9.9%)
184 (10.8%)
#DIV/0!
99 (7.2%)
98 (7.1%)
0.00
Bladder stones+Kidney stones (for PS); n 
(%)
21 (4.3%)
19 (3.9%)
0.02
39 (2.8%)
49 (3.5%)
-0.04
62 (3.6%)
64 (3.8%)
-0.01
122 (3.4%)
132 (3.7%)
-0.02
Alcohol abuse or dependence+Drug 
abuse or dependence (for PS); n (%)
33 (6.7%)
36 (7.3%)
-0.02
46 (3.3%)
49 (3.5%)
-0.01
156 (9.2%)
145 (8.5%)
0.02
235 (6.6%)
230 (6.4%)
0.01
Other atherosclerosis+Cardiac 
conduction disorders+Other CVD (for 
PS) v2 Copy; n (%)
155 (31.6%)
149 (30.4%)
0.03
394 (28.5%)
402 (29.1%)
-0.01
500 (29.4%)
539 (31.7%)
-0.05
1049 (29.4%)
1090 (30.5%)
-0.02
Appendix B 

Previous cardiac procedure (CABG or 
PTCA or Stent) + History of CABG or PTCA 
(for PS) v3; n (%)
22 (4.5%)
14 (2.9%)
0.08
14 (1.0%)
13 (0.9%)
0.01
91 (5.4%)
96 (5.7%)
-0.01
127 (3.6%)
123 (3.4%)
0.01
Diabetes with complication; n (%)
35 (7.1%)
32 (6.5%)
#DIV/0!
53 (3.8%)
50 (3.6%)
#DIV/0!
156 (9.2%)
167 (9.8%)
#DIV/0!
53 (3.8%)
50 (3.6%)
0.01
Delirium + Psychosis (for PS); n (%)
23 (4.7%)
26 (5.3%)
-0.03
30 (2.2%)
33 (2.4%)
-0.01
263 (15.5%)
262 (15.4%)
0.00
316 (8.9%)
321 (9.0%)
0.00
Any use of Meglitinides (for PS); n (%)
0 (0.0%)
** (0.2%)
-0.06
** (0.1%)
** (0.1%)
0.00
0 (0.0%)
0 (0.0%)
#DIV/0!
#VALUE!
#VALUE!
#VALUE!
Any use of AGIs (for PS); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
0 (0.0%)
0.04
0 (0.0%)
0 (0.0%)
#DIV/0!
#VALUE!
0 (0.0%)
#VALUE!
CKD stage 3-6 + dialysis (for PS); n (%)
16 (3.3%)
17 (3.5%)
-0.01
34 (2.5%)
25 (1.8%)
0.05
80 (4.7%)
94 (5.5%)
-0.04
130 (3.6%)
136 (3.8%)
-0.01
Use of thiazide; n (%)
22 (4.5%)
23 (4.7%)
-0.01
79 (5.7%)
88 (6.4%)
-0.03
79 (4.6%)
82 (4.8%)
-0.01
180 (5.0%)
193 (5.4%)
-0.02
Use of beta blockers; n (%)
75 (15.3%)
66 (13.5%)
0.05
231 (16.7%)
218 (15.8%)
0.02
331 (19.5%)
328 (19.3%)
0.01
637 (17.8%)
612 (17.1%)
0.02
Use of calcium channel blockers; n (%)
55 (11.2%)
56 (11.4%)
-0.01
170 (12.3%)
169 (12.2%)
0.00
194 (11.4%)
179 (10.5%)
0.03
419 (11.7%)
404 (11.3%)
0.01
All antidiabetic medications except Insuli
57 (11.6%)
62 (12.7%)
-0.03
149 (10.8%)
158 (11.4%)
-0.02
207 (12.2%)
219 (12.9%)
-0.02
413 (11.6%)
439 (12.3%)
-0.02
DM Medications - Insulin Copy; n (%)
23 (4.7%)
27 (5.5%)
-0.04
59 (4.3%)
49 (3.5%)
0.04
80 (4.7%)
91 (5.4%)
-0.03
162 (4.5%)
167 (4.7%)
-0.01
Use of Low Intensity Statins; n (%)
61 (12.4%)
63 (12.9%)
-0.02
136 (9.8%)
132 (9.6%)
0.01
283 (16.7%)
277 (16.3%)
0.01
480 (13.4%)
472 (13.2%)
0.01
Use of High Intensity Statins; n (%)
51 (10.4%)
51 (10.4%)
0.00
127 (9.2%)
132 (9.6%)
-0.01
195 (11.5%)
204 (12.0%)
-0.02
373 (10.4%)
387 (10.8%)
-0.01
Malignant hypertension; n (%)
** (0.2%)
** (0.2%)
0.00
76 (5.5%)
85 (6.2%)
-0.03
82 (4.8%)
73 (4.3%)
0.02
#VALUE!
#VALUE!
#VALUE!
Cardiovascular stress test; n (%)
** (1.0%)
** (0.4%)
0.07
** (0.6%)
** (0.7%)
-0.01
21 (1.2%)
26 (1.5%)
-0.03
#VALUE!
#VALUE!
#VALUE!
Echocardiogram; n (%)
298 (60.8%)
349 (71.2%)
-0.22
910 (65.9%)
960 (69.5%)
-0.08
1,040 (61.2%)
1,058 (62.3%)
-0.02
2248 (63.0%)
2367 (66.3%)
-0.07
Number of BNP tests
...mean (sd)
0.17 (0.51)
0.22 (0.59)
-0.09
0.15 (0.47)
0.17 (0.49)
-0.04
0.17 (0.51)
0.22 (0.53)
-0.10
0.16 (0.49)
0.20 (0.52)
0.00
Number of Cardiac biomarkers tests (tropnin, CK-MBs, Myoglobin, CPK)
...mean (sd)
0.46 (1.22)
0.73 (1.68)
-0.18
0.44 (1.13)
0.54 (1.46)
-0.08
0.39 (0.80)
0.46 (0.96)
-0.08
0.42 (1.00)
0.53 (1.28)
0.00
Number of Ambulatory Blood pressure monitoring tests
...mean (sd)
0.00 (0.00)
0.00 (0.06)
0.00
0.00 (0.04)
0.00 (0.03)
0.00
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.02)
0.00 (0.03)
0.00
N of days on antihypertensive medications during baseline
...mean (sd)
41.64 (66.76)
40.37 (67.11)
0.02
45.23 (70.39)
45.62 (70.62)
-0.01
41.49 (66.16)
43.81 (67.50)
-0.03
42.96 (67.91)
44.04 (68.67)
0.00
N of days in database anytime prior
...mean (sd)
1,631.36 (1,356.14)
1,568.20 (1,247.77)
0.05
2,203.52 (1,550.45)
2,092.63 (1,508.64)
0.07
720.02 (502.47)
681.78 (392.54)
0.08
1418.98 (1141.20)
1349.21 (1080.43)
0.00
Mean Copay for per prescription cost (charges in U.S. $) (180-1 day prior)
...mean (sd)
22.31 (49.02)
22.88 (47.07)
-0.01
11.22 (16.38)
10.92 (16.98)
0.02
111.13 (120.49)
117.56 (187.51)
-0.04
60.29 (85.70)
63.31 (130.97)
0.00
...Missing; n (%)
57 (11.6%)
59 (12.0%)
-0.01
156 (11.3%)
155 (11.2%)
0.00
182 (10.7%)
179 (10.5%)
0.01
395 (11.1%)
393 (11.0%)
0.00
Colonoscopy; n (%)
17 (3.5%)
20 (4.1%)
-0.03
55 (4.0%)
50 (3.6%)
0.02
47 (2.8%)
47 (2.8%)
0.00
119 (3.3%)
117 (3.3%)
0.00
Fecal occult blood (FOB) test; n (%)
14 (2.9%)
14 (2.9%)
0.00
47 (3.4%)
45 (3.3%)
0.01
33 (1.9%)
43 (2.5%)
-0.04
94 (2.6%)
102 (2.9%)
-0.02
Flu vaccine; n (%)
62 (12.7%)
57 (11.6%)
0.03
142 (10.3%)
144 (10.4%)
0.00
440 (25.9%)
432 (25.4%)
0.01
644 (18.0%)
633 (17.7%)
0.01
Mammogram; n (%)
43 (8.8%)
49 (10.0%)
-0.04
138 (10.0%)
152 (11.0%)
-0.03
152 (8.9%)
138 (8.1%)
0.03
333 (9.3%)
339 (9.5%)
-0.01
Pap smear; n (%)
26 (5.3%)
23 (4.7%)
0.03
98 (7.1%)
106 (7.7%)
-0.02
48 (2.8%)
54 (3.2%)
-0.02
172 (4.8%)
183 (5.1%)
-0.01
Pneumonia vaccine; n (%)
94 (19.2%)
85 (17.3%)
0.05
179 (13.0%)
178 (12.9%)
0.00
506 (29.8%)
501 (29.5%)
0.01
779 (21.8%)
764 (21.4%)
0.01
PSA test or Prostate exam for DRE; n (%)
42 (8.6%)
39 (8.0%)
0.02
132 (9.6%)
132 (9.6%)
0.00
134 (7.9%)
122 (7.2%)
0.03
308 (8.6%)
293 (8.2%)
0.01
Bone mineral density; n (%)
** (1.8%)
15 (3.1%)
-0.08
20 (1.4%)
21 (1.5%)
-0.01
39 (2.3%)
42 (2.5%)
-0.01
#VALUE!
78 (2.2%)
#VALUE!
Use of CNS stimulants; n (%)
** (1.6%)
** (1.8%)
-0.02
** (0.5%)
26 (1.9%)
-0.13
** (0.6%)
** (0.6%)
0.00
#VALUE!
#VALUE!
#VALUE!
Use of estrogens, progestins, androgens; n
48 (9.8%)
42 (8.6%)
0.04
175 (12.7%)
176 (12.7%)
0.00
62 (3.6%)
65 (3.8%)
-0.01
285 (8.0%)
283 (7.9%)
0.00
Use of Angiogenesis inhibitors; n (%)
0 (0.0%)
** (0.2%)
-0.06
** (0.1%)
** (0.1%)
0.00
** (0.1%)
** (0.2%)
-0.03
#VALUE!
#VALUE!
#VALUE!
Use of Oral Immunosuppressants; n (%)
** (0.2%)
** (0.2%)
0.00
** (0.4%)
** (0.2%)
0.04
** (0.2%)
** (0.2%)
0.00
#VALUE!
#VALUE!
#VALUE!
Use of fondaparinux or Bivalirudin; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
** (0.1%)
0.00
** (0.2%)
** (0.1%)
0.03
#VALUE!
#VALUE!
#VALUE!
Use of other direct thrombin inhibitors (l
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
Use of Ticagrelor ON CED; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
0 (0.0%)
0.04
0 (0.0%)
** (0.1%)
-0.04
#VALUE!
#VALUE!
#VALUE!
Use of Ticagrelor; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
** (0.1%)
0.00
0 (0.0%)
** (0.2%)
-0.06
#VALUE!
#VALUE!
#VALUE!
Number of D-dimer tests
...mean (sd)
0.19 (0.44)
0.19 (0.45)
0.00
0.17 (0.44)
0.18 (0.45)
-0.02
0.19 (0.45)
0.18 (0.43)
0.02
0.18 (0.44)
0.18 (0.44)
0.00
Numbe of CRP, high-sensitivity CRP tests
...mean (sd)
0.13 (0.58)
0.14 (0.77)
-0.01
0.10 (0.45)
0.09 (0.49)
0.02
0.13 (0.59)
0.13 (0.57)
0.00
0.12 (0.54)
0.12 (0.57)
0.00
Number of PT or aPTTt tests
...mean (sd)
1.03 (2.16)
1.03 (2.17)
0.00
0.85 (2.00)
0.81 (1.96)
0.02
0.53 (1.12)
0.52 (1.10)
0.01
0.72 (1.67)
0.70 (1.65)
0.00
Number of Bleeding time tests
...mean (sd)
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.00)
0.00 (0.00)
#DIV/0!
0.00 (0.00)
0.00 (0.00)
#DIV/0!
HAS-BLED Score (ICD-9 and ICD-10), 180 days
...mean (sd)
2.06 (0.69)
2.07 (0.63)
-0.02
1.90 (0.70)
1.90 (0.68)
0.00
2.38 (0.81)
2.39 (0.78)
-0.01
2.15 (0.75)
2.16 (0.72)
0.00
N of Generic name drugs
...mean (sd)
14.39 (14.69)
14.42 (16.73)
0.00
11.78 (10.46)
12.02 (13.21)
-0.02
19.11 (18.82)
19.05 (19.03)
0.00
15.63 (15.51)
15.70 (16.68)
0.00
N of Brand name drugs
...mean (sd)
2.59 (4.40)
2.63 (2.88)
-0.01
2.47 (3.76)
2.53 (2.57)
-0.02
3.47 (5.81)
3.51 (3.78)
-0.01
2.96 (4.92)
3.01 (3.24)
0.00
Use of clopidogrel ; n (%)
** (0.6%)
** (0.8%)
-0.02
** (0.5%)
** (0.5%)
0.00
68 (4.0%)
62 (3.6%)
0.02
#VALUE!
#VALUE!
#VALUE!
Systemic embolism; n (%)
** (1.8%)
12 (2.4%)
-0.04
26 (1.9%)
28 (2.0%)
-0.01
29 (1.7%)
29 (1.7%)
0.00
#VALUE!
69 (1.9%)
#VALUE!
DVT; n (%)
257 (52.4%)
248 (50.6%)
0.04
757 (54.8%)
739 (53.5%)
0.03
824 (48.5%)
849 (50.0%)
-0.03
1838 (51.5%)
1836 (51.4%)
0.00
Post-thrombotic syndrome; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
** (0.1%)
#DIV/0!
** (0.2%)
** (0.1%)
#DIV/0!
** (0.1%)
** (0.1%)
0.00
PE; n (%)
490 (100.0%)
490 (100.0%)
#DIV/0!
1,381 (100.0%)
1,381 (100.0%)
#DIV/0!
1,692 (99.6%)
1,695 (99.8%)
-0.04
3563 (99.8%)
3566 (99.9%)
-0.03
Coagulation defects; n (%)
** (1.6%)
** (2.2%)
#DIV/0!
35 (2.5%)
40 (2.9%)
#DIV/0!
28 (1.6%)
32 (1.9%)
35 (2.5%)
40 (2.9%)
-0.02
Diabetes: 1 inpatient or 2 outpatient claim
86 (17.6%)
90 (18.4%)
-0.02
212 (15.4%)
210 (15.2%)
0.01
371 (21.8%)
407 (24.0%)
-0.05
669 (18.7%)
707 (19.8%)
-0.03
Appendix B 

Intracranial or retroperitoneal hemorrha
** (0.4%)
** (0.4%)
0.00
** (0.1%)
** (0.1%)
0.00
** (0.3%)
** (0.2%)
0.02
#VALUE!
#VALUE!
#VALUE!
Peptic Ulcer Disease; n (%)
134 (27.3%)
140 (28.6%)
-0.03
257 (18.6%)
268 (19.4%)
-0.02
534 (31.4%)
545 (32.1%)
-0.02
925 (25.9%)
953 (26.7%)
-0.02
Upper GI bleed; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
** (0.1%)
0.00
** (0.2%)
** (0.1%)
0.03
#VALUE!
#VALUE!
#VALUE!
Lower/ unspecified GI bleed; n (%)
** (1.6%)
** (1.4%)
0.02
22 (1.6%)
20 (1.4%)
0.02
19 (1.1%)
20 (1.2%)
-0.01
#VALUE!
#VALUE!
#VALUE!
Urogenital bleed; n (%)
** (1.8%)
12 (2.4%)
-0.04
48 (3.5%)
41 (3.0%)
0.03
37 (2.2%)
48 (2.8%)
-0.04
#VALUE!
101 (2.8%)
#VALUE!
Other bleeds; n (%)
18 (3.7%)
18 (3.7%)
0.00
55 (4.0%)
53 (3.8%)
0.01
70 (4.1%)
63 (3.7%)
0.02
143 (4.0%)
134 (3.8%)
0.01
Prior cancer; n (%)
78 (15.9%)
79 (16.1%)
-0.01
174 (12.6%)
176 (12.7%)
0.00
349 (20.5%)
334 (19.7%)
0.02
601 (16.8%)
589 (16.5%)
0.01
Antibiotics; n (%)
234 (47.8%)
235 (48.0%)
#DIV/0!
664 (48.1%)
671 (48.6%)
#DIV/0!
857 (50.4%)
853 (50.2%)
#DIV/0!
664 (48.1%)
671 (48.6%)
-0.01
Aspirin; n (%)
** (0.4%)
** (0.6%)
-0.03
14 (1.0%)
19 (1.4%)
-0.04
** (0.2%)
** (0.1%)
0.03
#VALUE!
#VALUE!
#VALUE!
Aspirin/dipyridamole; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
** (0.1%)
** (0.1%)
0.00
#VALUE!
#VALUE!
#VALUE!
Other antiplatelet agents; n (%)
** (0.2%)
0 (0.0%)
0.06
** (0.1%)
** (0.1%)
0.00
** (0.4%)
** (0.3%)
0.02
#VALUE!
#VALUE!
#VALUE!
PGP inhibitors; n (%)
103 (21.0%)
92 (18.8%)
0.06
306 (22.2%)
316 (22.9%)
-0.02
410 (24.1%)
404 (23.8%)
0.01
819 (22.9%)
812 (22.7%)
0.00
Other gastroprotective agents; n (%)
** (1.0%)
** (0.6%)
0.04
14 (1.0%)
13 (0.9%)
0.01
35 (2.1%)
26 (1.5%)
0.05
#VALUE!
#VALUE!
#VALUE!
Number of lipid tests ordered
...mean (sd)
0.37 (0.62)
0.39 (0.74)
-0.03
0.38 (0.72)
0.36 (0.66)
0.03
0.37 (0.69)
0.38 (0.68)
-0.01
0.37 (0.69)
0.37 (0.68)
0.00
Proton pump inhibitor; n (%)
94 (19.2%)
105 (21.4%)
-0.05
232 (16.8%)
225 (16.3%)
0.01
494 (29.1%)
490 (28.8%)
0.01
820 (23.0%)
820 (23.0%)
0.00
H2 receptor antagonist; n (%)
15 (3.1%)
21 (4.3%)
-0.06
47 (3.4%)
49 (3.5%)
-0.01
128 (7.5%)
139 (8.2%)
-0.03
190 (5.3%)
209 (5.9%)
-0.03
Vitamin K therapy; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
Number of INR (prothrombin) tests ordered
...mean (sd)
0.80 (1.89)
0.53 (1.24)
0.17
0.68 (1.73)
0.50 (1.11)
0.12
0.51 (1.10)
0.49 (1.06)
0.02
0.62 (1.49)
0.50 (1.11)
0.00
Treating prescriber - Cardiologist; n (%)
299 (61.0%)
313 (63.9%)
-0.06
871 (63.1%)
868 (62.9%)
0.00
880 (51.8%)
902 (53.1%)
-0.03
2050 (57.4%)
2083 (58.3%)
-0.02
Treating prescriber - Primary Care Physici
415 (84.7%)
407 (83.1%)
0.04
600 (43.4%)
636 (46.1%)
-0.05
642 (37.8%)
637 (37.5%)
0.01
1657 (46.4%)
1680 (47.1%)
-0.01
Treating prescriber - Other; n (%)
474 (96.7%)
476 (97.1%)
-0.02
1,287 (93.2%)
1,288 (93.3%)
0.00
1,613 (94.9%)
1,617 (95.2%)
-0.01
3374 (94.5%)
3381 (94.7%)
-0.01
Alpha blockers; n (%)
30 (6.1%)
21 (4.3%)
0.08
54 (3.9%)
56 (4.1%)
-0.01
123 (7.2%)
125 (7.4%)
-0.01
207 (5.8%)
202 (5.7%)
0.00
CHA2DS2 VASc score, 180 days, V
...mean (sd)
1.49 (1.21)
1.52 (1.17)
-0.03
1.24 (1.16)
1.25 (1.21)
-0.01
1.55 (1.37)
1.56 (1.36)
-0.01
1.42 (1.27)
1.43 (1.28)
0.00
Use of Prasugrel; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
Use of Loop Diuretics+other diuretics+oth
66 (13.5%)
66 (13.5%)
0.00
138 (10.0%)
139 (10.1%)
0.00
312 (18.4%)
334 (19.7%)
-0.03
516 (14.5%)
539 (15.1%)
-0.02
Commercial vs Medicare Advantage- Business Type Code - CORRECT ONE - OPTUM
0
0
...Commercial; n (%)
260 (53.1%)
249 (50.8%)
0.05
#VALUE!
#VALUE!
#VALUE!
-
-
#VALUE!
#VALUE!
#VALUE!
#VALUE!
...Medicare Advantage; n (%)
0,230 (46.9%)
241 (49.2%)
-0.05
1287 (93.2%)
1285 (93.0%)
0.01
-
-
#VALUE!
#VALUE!
1,526 (81.6%)
#VALUE!
Commercial vs Medicare Advantage- Business Type Code
...COM = COMMERCIAL; n (%)
260 (53.1%)
249 (50.8%)
0.05
-
-
#VALUE!
-
-
#VALUE!
260 (53.1%)
249 (50.8%)
0.05
...MCR = MEDICARE; n (%)
230 (46.9%)
241 (49.2%)
-0.05
-
-
#VALUE!
-
-
#VALUE!
230 (46.9%)
241 (49.2%)
-0.05
...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...NONE = NO BUSINESS LINE CODE (added
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- Data
-
-
0
0
-
-
...1 - Fee For Service; n (%)
-
-
1,156 (83.7%)
1,158 (83.9%)
-
-
1,156 (83.7%)
1,158 (83.9%)
0.00
...2 - Encounter; n (%)
-
-
131 (9.5%)
127 (9.2%)
-
-
131 (9.5%)
127 (9.2%)
0.00
...3 - Medicare; n (%)
-
-
85 (6.2%)
86 (6.2%)
-
-
85 (6.2%)
86 (6.2%)
0.00
...4 - Medicare Encounter; n (%)
-
-
** (0.7%)
** (0.7%)
-
-
** (0.7%)
** (0.7%)
0.00
Metropolitan Statistical Area - Urban (any MSA) vs Rural (non-MSA)
0
0
0.00
...Urban; n (%)
-
-
998 (72.3%)
993 (71.9%)
-
-
998 (72.3%)
993 (71.9%)
0.00
...Rural; n (%)
-
-
151 (10.9%)
153 (11.1%)
-
-
151 (10.9%)
153 (11.1%)
0.00
...Unknown/Missing; n (%)
-
-
232 (16.8%)
235 (17.0%)
-
-
232 (16.8%)
235 (17.0%)
0.00
Appendix B